Drug Patents Expiring in 2033

1. Abilify Asimtufii patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11638757 OTSUKA Injectable preparation
Apr, 2033

(8 years from now)

US11097007 OTSUKA Injectable preparation
Apr, 2033

(8 years from now)

US10517951 OTSUKA Injectable preparation
Apr, 2033

(8 years from now)

US12016927 OTSUKA Injectable preparation
Apr, 2033

(8 years from now)




Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 27 April, 2023

Treatment: Treatment of schizophrenia; Maintenance monotherapy treatment of bipolar i disorder

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

ABILIFY ASIMTUFII family patents

Family Patents

2. Abilify Maintena Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11154553 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(8 years from now)

US11344547 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(8 years from now)

US10980803 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(8 years from now)

US11400087 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Feb 28, 2016
M(M-150) Dec 05, 2017
New Indication(I-746) Jul 27, 2020

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 28 February, 2013

Treatment: Maintenance monotherapy treatment of bipolar i disorder; Treatment of schizophrenia; Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE

How can I launch a generic of ABILIFY MAINTENA KIT before it's drug patent expiration?
More Information on Dosage

ABILIFY MAINTENA KIT family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Abilify Mycite Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9577864 OTSUKA Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance
Oct, 2033

(8 years from now)

US9268909 OTSUKA Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device
Oct, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-150) Dec 05, 2017
New Indication(I-746) Jul 27, 2020

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: Method of using a receiver to identify a signal from a tablet embedded with a sensor that communicates information through the body of a patient; Method of using a logic circuit to stabilize battery v...

Dosage: TABLET

More Information on Dosage

ABILIFY MYCITE KIT family patents

Family Patents

4. Aczone patent expiration

ACZONE IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9517219 ALMIRALL Topical dapsone and dapsone/adapalene compositions and methods for use thereof
Nov, 2033

(8 years from now)

US11273132 ALMIRALL Topical dapsone and dapsone/adapalene compositions and methods for use thereof
Nov, 2033

(8 years from now)

US9161926 ALMIRALL Topical dapsone and dapsone/adaplene compositions and methods for use thereof
Nov, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Strength(NS) Feb 24, 2019
New Patient Population(NPP) Sep 10, 2022

Drugs and Companies using DAPSONE ingredient

Market Authorisation Date: 24 February, 2016

Treatment: Topical treatment of acne vulgaris

Dosage: GEL

How can I launch a generic of ACZONE before it's drug patent expiration?
More Information on Dosage

ACZONE family patents

Family Patents

5. Admelog Solostar patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9717852 SANOFI-AVENTIS US Cartridge holder and pen-type injector
Apr, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 11, 2020

Drugs and Companies using INSULIN LISPRO ingredient

Market Authorisation Date: 11 December, 2017

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

ADMELOG SOLOSTAR family patents

Family Patents

6. Agamree patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11690853 CATALYST PHARMS Non-hormonal steroid modulators of NF-κβ for treatment of disease
Mar, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 26, 2028
Orphan Drug Exclusivity(ODE-450) Oct 26, 2030

Drugs and Companies using VAMOROLONE ingredient

NCE-1 date: 27 October, 2027

Market Authorisation Date: 26 October, 2023

Treatment: Treatment of duchenne muscular dystrophy

Dosage: SUSPENSION

More Information on Dosage

AGAMREE family patents

Family Patents

7. Aklief patent expiration

AKLIEF's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9084778 GALDERMA LABS LP Topical compositions containing a retinoid of the oil-in-water emulsion type
May, 2033

(8 years from now)

US9498465 GALDERMA LABS LP Topical compositions in the form of a gel containing a particular solubilized retinoid
May, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 04, 2024

Drugs and Companies using TRIFAROTENE ingredient

NCE-1 date: 05 October, 2023

Market Authorisation Date: 04 October, 2019

Treatment: Treatment of acne vulgaris; Topical treatment of acne vulgaris

Dosage: CREAM

More Information on Dosage

AKLIEF family patents

Family Patents

8. Alkindi Sprinkle patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9675559 ETON Treatment of adrenal insufficiency
Jan, 2033

(8 years from now)




Drugs and Companies using HYDROCORTISONE ingredient

Market Authorisation Date: 29 September, 2020

Treatment: Treatment of adrenal insufficiency

Dosage: GRANULE

More Information on Dosage

ALKINDI SPRINKLE family patents

Family Patents

9. Antara (micronized) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9314447 LUPIN Reduced dose pharmaceutical compositions of fenofibrate
May, 2033

(8 years from now)




Drugs and Companies using FENOFIBRATE ingredient

Market Authorisation Date: 30 November, 2004

Treatment: Treating severe hypertriglyceridemia

Dosage: CAPSULE

How can I launch a generic of ANTARA (MICRONIZED) before it's drug patent expiration?
More Information on Dosage

ANTARA (MICRONIZED) family patents

Family Patents

10. Apidra Solostar patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9717852 SANOFI AVENTIS US Cartridge holder and pen-type injector
Apr, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Oct 24, 2011

Drugs and Companies using INSULIN GLULISINE RECOMBINANT ingredient

Market Authorisation Date: 16 April, 2004

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

APIDRA SOLOSTAR family patents

Family Patents

11. Aristada patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9193685 ALKERMES INC Pharmaceutical compositions having improved storage stability
Oct, 2033

(8 years from now)

US11097006 ALKERMES INC Pharmaceutical compositions having improved storage stability
Oct, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 05, 2020

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

NCE-1 date: 06 October, 2019

Market Authorisation Date: 05 October, 2015

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

ARISTADA family patents

Family Patents

12. Arymo Er patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549899 ZYLA Abuse deterrent pharmaceutical compositions for controlled release
Jul, 2033

(8 years from now)

US9044402 ZYLA Abuse-deterrent pharmaceutical compositions for controlled release
Jul, 2033

(8 years from now)




Drugs and Companies using MORPHINE SULFATE ingredient

Market Authorisation Date: 09 January, 2017

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of ARYMO ER before it's drug patent expiration?
More Information on Dosage

ARYMO ER family patents

Family Patents

13. Austedo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9550780 TEVA BRANDED PHARM Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9233959 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(8 years from now)

US9814708 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(8 years from now)

US9296739 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(8 years from now)

US11666566 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-751) Aug 30, 2020
New Chemical Entity Exclusivity(NCE) Apr 03, 2022
Orphan Drug Exclusivity(ODE) Apr 03, 2024
Orphan Drug Exclusivity(ODE-134) Apr 03, 2024
M(M-54) Jun 24, 2024
Pediatric Exclusivity(PED) Dec 24, 2024

Drugs and Companies using DEUTETRABENAZINE ingredient

NCE-1 date: 25 December, 2023

Market Authorisation Date: 03 April, 2017

Treatment: A method of treating huntington's chorea

Dosage: TABLET

How can I launch a generic of AUSTEDO before it's drug patent expiration?
More Information on Dosage

AUSTEDO family patents

Family Patents

14. Austedo Xr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9550780 TEVA Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(8 years from now)




Drugs and Companies using DEUTETRABENAZINE ingredient

Market Authorisation Date: 17 February, 2023

Treatment: Treatment of tardive dyskinesia

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

AUSTEDO XR family patents

Family Patents

15. Auvelity patent expiration

Can you believe AUVELITY received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8569328 AXSOME Compositions and methods comprising tilidine or related compounds and dextromethorphan
Oct, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 18, 2025

Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient

Market Authorisation Date: 18 August, 2022

Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of AUVELITY before it's drug patent expiration?
More Information on Dosage

AUVELITY family patents

Family Patents

16. Balversa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8895601 JANSSEN BIOTECH Pyrazolyl quinoxaline kinase inhibitors
Apr, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 12, 2024
New Indication(I-930) Jan 19, 2027

Drugs and Companies using ERDAFITINIB ingredient

NCE-1 date: 13 April, 2023

Market Authorisation Date: 12 April, 2019

Treatment: NA

Dosage: TABLET

How can I launch a generic of BALVERSA before it's drug patent expiration?
More Information on Dosage

BALVERSA family patents

Family Patents

17. Baxdela patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9493582 MELINTA Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 19, 2022
New Indication(I-815) Oct 24, 2022
Generating Antibiotic Incentives Now(GAIN) Jun 19, 2027

Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient

NCE-1 date: 19 June, 2026

Market Authorisation Date: 19 June, 2017

Treatment: NA

Dosage: POWDER

More Information on Dosage

BAXDELA family patents

Family Patents

18. Belsomra patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11980623 MERCK SHARP DOHME Solid dosage formulations of an orexin receptor antagonist
May, 2033

(8 years from now)

US10098892 MERCK SHARP DOHME Solid dosage formulations of an orexin receptor antagonist
May, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 13, 2019
M(M-253) Jan 29, 2023

Drugs and Companies using SUVOREXANT ingredient

NCE-1 date: 13 August, 2018

Market Authorisation Date: 13 August, 2014

Treatment: NA

Dosage: TABLET

More Information on Dosage

BELSOMRA family patents

Family Patents

19. Belviq patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8999970 EISAI INC Administration of an anti-obesity compound to individuals with renal impairment
Feb, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 27, 2017

Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient

NCE-1 date: 27 June, 2016

Market Authorisation Date: 27 June, 2012

Treatment: Method for chronic weight management by decreasing food intake in an individual who does not have severe renal impairment or esrd

Dosage: TABLET

How can I launch a generic of BELVIQ before it's drug patent expiration?
More Information on Dosage

BELVIQ family patents

Family Patents

20. Belviq Xr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8999970 EISAI INC Administration of an anti-obesity compound to individuals with renal impairment
Feb, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 27, 2017

Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient

NCE-1 date: 27 June, 2016

Market Authorisation Date: 15 July, 2016

Treatment: Method for chronic weight management by treating obesity in an individual who does not have severe renal impairment or esrd

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of BELVIQ XR before it's drug patent expiration?
More Information on Dosage

BELVIQ XR family patents

Family Patents

21. Bendeka patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9572887 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(8 years from now)

US9597398 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(8 years from now)

US9579384 EAGLE PHARMS Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
Mar, 2033

(8 years from now)

US10052385 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(8 years from now)

US9034908 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(8 years from now)

US9597399 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(8 years from now)

US9144568 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(8 years from now)

US9000021 EAGLE PHARMS Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
Mar, 2033

(8 years from now)

US9597397 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-179) Dec 07, 2022

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 07 December, 2015

Treatment: For the treatment of patients with chronic lymphocytic leukemia; For the treatment of patients with indolent b-cell non-hodgkin lymphoma; For use in the treatment of patients with chronic lymphocytic ...

Dosage: SOLUTION

How can I launch a generic of BENDEKA before it's drug patent expiration?
More Information on Dosage

BENDEKA family patents

Family Patents

22. Biktarvy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9216996 GILEAD SCIENCES INC Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections
Dec, 2033

(8 years from now)

US9732092 GILEAD SCIENCES INC Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections
Dec, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8754065

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(8 years from now)

US9296769

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jun 18, 2022
New Chemical Entity Exclusivity(NCE) Feb 07, 2023
M(M-82) Feb 24, 2024
Orphan Drug Exclusivity(ODE-256) Jun 18, 2026
New Indication(I-942) Feb 23, 2027
M(M-305) Apr 24, 2027
Orphan Drug Exclusivity(ODE-378) Oct 07, 2028
Orphan Drug Exclusivity(ODE-468) Feb 23, 2031

Drugs and Companies using BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 07 February, 2022

Market Authorisation Date: 07 October, 2021

Treatment: NA

Dosage: TABLET

How can I launch a generic of BIKTARVY before it's drug patent expiration?
More Information on Dosage

BIKTARVY family patents

Family Patents

23. Bonjesta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9089489 DUCHESNAY Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
Feb, 2033

(8 years from now)

US9375404 DUCHESNAY Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
Feb, 2033

(8 years from now)

US9526703 DUCHESNAY Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
Feb, 2033

(8 years from now)

US9937132 DUCHESNAY Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
Feb, 2033

(8 years from now)




Drugs and Companies using DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE ingredient

Market Authorisation Date: 07 November, 2016

Treatment: Treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of BONJESTA before it's drug patent expiration?
More Information on Dosage

BONJESTA family patents

Family Patents

24. Braftovi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9474754 ARRAY BIOPHARMA INC Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor
Aug, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-826) Apr 08, 2023
New Chemical Entity Exclusivity(NCE) Jun 27, 2023
Orphan Drug Exclusivity(ODE-194) Jun 27, 2025
New Indication(I-928) Oct 11, 2026
Orphan Drug Exclusivity(ODE-445) Oct 11, 2030

Drugs and Companies using ENCORAFENIB ingredient

NCE-1 date: 27 June, 2022

Market Authorisation Date: 27 June, 2018

Treatment: Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-ap...

Dosage: CAPSULE

How can I launch a generic of BRAFTOVI before it's drug patent expiration?
More Information on Dosage

BRAFTOVI family patents

Family Patents

25. Byfavo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9561236 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Apr, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 06, 2025

Drugs and Companies using REMIMAZOLAM BESYLATE ingredient

NCE-1 date: 06 October, 2024

Market Authorisation Date: 06 October, 2020

Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less

Dosage: POWDER

More Information on Dosage

BYFAVO family patents

Family Patents

26. Cabometyx patent expiration

CABOMETYX's oppositions filed in EPO
Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9724342 EXELIXIS INC C-met modulator pharmaceutical compositions
Jul, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 29, 2017
New Product(NP) Apr 25, 2019
New Indication(I-760) Dec 19, 2020
New Indication(I-792) Jan 14, 2022
New Indication(I-854) Jan 22, 2024
New Indication(I-873) Sep 17, 2024
Orphan Drug Exclusivity(ODE-227) Jan 14, 2026
Orphan Drug Exclusivity(ODE-375) Sep 17, 2028

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

NCE-1 date: 29 November, 2016

Market Authorisation Date: 25 April, 2016

Treatment: NA

Dosage: TABLET

How can I launch a generic of CABOMETYX before it's drug patent expiration?
More Information on Dosage

CABOMETYX family patents

Family Patents

27. Caplyta patent expiration

Can you believe CAPLYTA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48839 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders
Aug, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-882) Dec 17, 2024
New Chemical Entity Exclusivity(NCE) Dec 20, 2024

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

NCE-1 date: 21 December, 2023

Market Authorisation Date: 22 April, 2022

Treatment: Treatment of schizophrenia

Dosage: CAPSULE

More Information on Dosage

CAPLYTA family patents

Family Patents

28. Carnexiv patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9493582 LUNDBECK PHARMS LLC Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Oct 07, 2023
Orphan Drug Exclusivity(ODE-124) Oct 07, 2023

Drugs and Companies using CARBAMAZEPINE ingredient

Market Authorisation Date: 07 October, 2016

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

CARNEXIV family patents

Family Patents

29. Cequa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9937225 SUN PHARM Topical formulations and uses thereof
Aug, 2033

(8 years from now)

US10441630 SUN PHARM Topical formulations and uses thereof
Aug, 2033

(8 years from now)

US8980839 SUN PHARM Topical aqueous nanomicellar, ophthalmic solutions and uses thereof
Aug, 2033

(8 years from now)




Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 14 August, 2018

Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Dosage: SOLUTION

More Information on Dosage

CEQUA family patents

Family Patents

30. Clorotekal patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9504666 B BRAUN MEDICAL INC Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration
Dec, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 26, 2020

Drugs and Companies using CHLOROPROCAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 26 September, 2017

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

CLOROTEKAL family patents

Family Patents

31. Complera patent expiration

COMPLERA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10857102 GILEAD SCIENCES INC Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate
Jan, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 20, 2016
New Patient Population(NPP) Dec 13, 2016

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE ingredient

NCE-1 date: 21 May, 2015

Market Authorisation Date: 10 August, 2011

Treatment: NA

Dosage: TABLET

How can I launch a generic of COMPLERA before it's drug patent expiration?
More Information on Dosage

COMPLERA family patents

Family Patents

32. Contrave patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11139056 NALPROPION Methods of treating overweight and obesity
Jun, 2033

(8 years from now)

US10403170 NALPROPION Methods of treating overweight and obesity
Jun, 2033

(8 years from now)

US9633575 NALPROPION Methods of treating overweight and obesity
Jun, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Sep 10, 2017

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: For chronic weight management for treating overweight or obesity

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of CONTRAVE before it's drug patent expiration?
More Information on Dosage

CONTRAVE family patents

Family Patents

33. Cytalux patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10881747 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(8 years from now)

US9789208 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(8 years from now)

US9061057 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(8 years from now)

US9333270 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(8 years from now)

US9341629 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(8 years from now)

US9254341 ON TARGET LABS Methods of manufacture of pteroyl-amino acid-fluorescent dyes
Oct, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-905) Dec 16, 2025
New Chemical Entity Exclusivity(NCE) Nov 29, 2026
Orphan Drug Exclusivity(ODE-390) Nov 29, 2028

Drugs and Companies using PAFOLACIANINE SODIUM ingredient

NCE-1 date: 29 November, 2025

Market Authorisation Date: 29 November, 2021

Treatment: Cytalux is an optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions

Dosage: SOLUTION

More Information on Dosage

CYTALUX family patents

Family Patents

34. Daptomycin patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10357535 HOSPIRA Daptomycin formulations and uses thereof
Sep, 2033

(8 years from now)

US9655946 HOSPIRA Daptomycin formulations and uses thereof
Sep, 2033

(8 years from now)




Drugs and Companies using DAPTOMYCIN ingredient

Market Authorisation Date: 21 June, 2021

Treatment: Treatment of complicated skin and skin structure infections and s. aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by reconstituting and administerin...

Dosage: POWDER

More Information on Dosage

DAPTOMYCIN family patents

Family Patents

35. Descovy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9296769

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(8 years from now)

US8754065

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Sep 28, 2020
New Chemical Entity Exclusivity(NCE) Nov 05, 2020
New Indication(I-812) Oct 03, 2022
Orphan Drug Exclusivity(ODE-284) Sep 28, 2024
Orphan Drug Exclusivity(ODE-285) Sep 28, 2024
Orphan Drug Exclusivity(ODE-457) Jan 07, 2029

Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 07 January, 2022

Treatment: NA

Dosage: TABLET

How can I launch a generic of DESCOVY before it's drug patent expiration?
More Information on Dosage

DESCOVY family patents

Family Patents

36. Docetaxel patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9308195 SHILPA Non-aqueous taxane formulations and methods of using the same
Sep, 2033

(8 years from now)

US8940786 SHILPA Non-aqueous taxane nanodispersion formulations and methods of using the same
Sep, 2033

(8 years from now)

US9763880 SHILPA Non-aqueous taxane formulations and methods of using the same
Sep, 2033

(8 years from now)




Drugs and Companies using DOCETAXEL ingredient

Market Authorisation Date: 22 December, 2015

Treatment: Method of administering an ethanol-free taxane liquid nanodispersion formulation to a subject combining the formulation with an aqueous medium to provide an ethanol-free taxane diluted solution; Treat...

Dosage: INJECTABLE

More Information on Dosage

DOCETAXEL family patents

Family Patents

37. Empaveli patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11661441 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
Jan, 2033

(8 years from now)

US10125171 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
Aug, 2033

(8 years from now)

US11292815 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(8 years from now)

US10875893 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(8 years from now)

US10035822 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-288) Feb 08, 2026
New Chemical Entity Exclusivity(NCE) May 14, 2026
Orphan Drug Exclusivity(ODE-351) May 14, 2028

Drugs and Companies using PEGCETACOPLAN ingredient

NCE-1 date: 14 May, 2025

Market Authorisation Date: 14 May, 2021

Treatment: Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of pegcetacoplan; Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administrat...

Dosage: SOLUTION

More Information on Dosage

EMPAVELI family patents

Family Patents

38. Entresto patent expiration

ENTRESTO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9937143 NOVARTIS PHARMS CORP Inhibitors for treating diseases characterized by atrial enlargement or remodeling
Aug, 2033

(8 years from now)

US9517226 NOVARTIS PHARMS CORP Inhibitors for treating diseases characterized by atrial enlargement or remodeling
Aug, 2033

(8 years from now)

US11135192 NOVARTIS PHARMS CORP Inhibitors for treating diseases characterized by atrial enlargement or remodeling
Aug, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 07, 2020
New Patient Population(NPP) Oct 01, 2022
Pediatric Exclusivity(PED) Apr 01, 2023
M(M-82) Feb 16, 2024

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

NCE-1 date: 01 April, 2022

Market Authorisation Date: 07 July, 2015

Treatment: Treatment of heart failure with preserved ejection fraction

Dosage: TABLET

How can I launch a generic of ENTRESTO before it's drug patent expiration?
More Information on Dosage

ENTRESTO family patents

Family Patents

39. Epanova patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9050309 ASTRAZENECA DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Jan, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9050308 ASTRAZENECA DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Jan, 2033

(8 years from now)

US10117844 ASTRAZENECA DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Jan, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 05, 2019

Drugs and Companies using OMEGA-3-CARBOXYLIC ACIDS ingredient

NCE-1 date: 05 May, 2018

Market Authorisation Date: 05 May, 2014

Treatment: Treatment of hypertriglyceridemia; Treatment of severe hypertriglyceridemia (500 mg/dl) in adult patients as an adjunct to diet

Dosage: CAPSULE

More Information on Dosage

EPANOVA family patents

Family Patents

40. Epclusa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8940718

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(8 years from now)

US8575135

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(8 years from now)

US8921341

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 28, 2021
New Dosing Schedule(D-177) Nov 15, 2022
New Patient Population(NPP) Mar 19, 2023
New Strength(NS) Mar 19, 2023
M(M-264) Jul 14, 2023
M(M-277) Apr 27, 2025
Orphan Drug Exclusivity(ODE-293) Mar 19, 2027
Orphan Drug Exclusivity(ODE-376) Jun 10, 2028
Pediatric Exclusivity(PED) Dec 10, 2028

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

Market Authorisation Date: 10 June, 2021

Treatment: NA

Dosage: PELLETS; TABLET

More Information on Dosage

EPCLUSA family patents

Family Patents

41. Erleada patent expiration

ERLEADA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9481663 JANSSEN BIOTECH Crystalline forms of an androgen receptor modulator
Jun, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10849888 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Sep, 2033

(8 years from now)

USRE49353 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Sep, 2033

(8 years from now)

US9884054 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Sep, 2033

(8 years from now)

US10052314 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Sep, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-808) Sep 17, 2022
New Chemical Entity Exclusivity(NCE) Feb 14, 2023

Drugs and Companies using APALUTAMIDE ingredient

NCE-1 date: 14 February, 2022

Market Authorisation Date: 14 February, 2018

Treatment: Treatment in combination with orchiectomy of non-metastatic, castration-resistant prostate cancer (nmcrpc); Treatment in combination with a gnrh agonist of non-metastatic, castration-resistant prostat...

Dosage: TABLET

How can I launch a generic of ERLEADA before it's drug patent expiration?
More Information on Dosage

ERLEADA family patents

Family Patents

42. Esbriet patent expiration

ESBRIET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778947 GENENTECH INC Methods of administering pirfenidone therapy
Aug, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 15, 2019
Orphan Drug Exclusivity(ODE) Oct 15, 2021
Orphan Drug Exclusivity(ODE-77) Oct 15, 2021

Drugs and Companies using PIRFENIDONE ingredient

NCE-1 date: 15 October, 2018

Market Authorisation Date: 15 October, 2014

Treatment: Administration of pirfenidone and avoiding concurrent administration of ciprofloxacin at a dose of 750 mg to reduce drug interactions in treatment of a fibrotic, inflammatory, or autoimmune disorder

Dosage: TABLET

How can I launch a generic of ESBRIET before it's drug patent expiration?
More Information on Dosage

ESBRIET family patents

Family Patents

43. Esmolol Hydrochloride Double Strength In Plastic Container patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8829054 HQ SPCLT PHARMA Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container
Mar, 2033

(8 years from now)

US8835505 HQ SPCLT PHARMA Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container
Mar, 2033

(8 years from now)




Drugs and Companies using ESMOLOL HYDROCHLORIDE ingredient

Market Authorisation Date: 07 April, 2016

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER family patents

Family Patents

44. Esmolol Hydrochloride In Plastic Container patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835505 HQ SPCLT PHARMA Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container
Mar, 2033

(8 years from now)

US8829054 HQ SPCLT PHARMA Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container
Mar, 2033

(8 years from now)




Drugs and Companies using ESMOLOL HYDROCHLORIDE ingredient

Market Authorisation Date: 07 April, 2016

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER family patents

Family Patents

45. Evomela patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9493582 ACROTECH BIOPHARMA Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Mar 10, 2023
Orphan Drug Exclusivity(ODE-110) Mar 10, 2023

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Market Authorisation Date: 10 March, 2016

Treatment: NA

Dosage: POWDER

How can I launch a generic of EVOMELA before it's drug patent expiration?
More Information on Dosage

EVOMELA family patents

Family Patents

46. Evrysdi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9586955 GENENTECH INC Compounds for treating spinal muscular atrophy
Feb, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) May 27, 2025
New Chemical Entity Exclusivity(NCE) Aug 07, 2025
M(M-270) Oct 03, 2026
Orphan Drug Exclusivity(ODE-334) Aug 07, 2027
Orphan Drug Exclusivity(ODE-400) May 27, 2029

Drugs and Companies using RISDIPLAM ingredient

NCE-1 date: 07 August, 2024

Market Authorisation Date: 07 August, 2020

Treatment: NA

Dosage: FOR SOLUTION

More Information on Dosage

EVRYSDI family patents

Family Patents

47. Eysuvis patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10993908 ALCON LABS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(8 years from now)

US9393213 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(8 years from now)

US11642317 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(8 years from now)

US11596599 ALCON LABS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(8 years from now)

US11872318 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(8 years from now)

US9827191 ALCON LABS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(8 years from now)

US9532955 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(8 years from now)

US9737491 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(8 years from now)

US11219596 ALCON LABS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(8 years from now)

US9056057 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(8 years from now)

US10688045 ALCON LABS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(8 years from now)

US10646436 ALCON LABS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(8 years from now)

US10857096 ALCON LABS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(8 years from now)

US10940108 ALCON LABS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(8 years from now)

US10945948 ALCON LABS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(8 years from now)

US10058511 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 26, 2023

Drugs and Companies using LOTEPREDNOL ETABONATE ingredient

Market Authorisation Date: 26 October, 2020

Treatment: Administration to the eye of a patient for treatment of dry eye condition; A method for treating dry eye in a patient; A method for delivering a composition to a mucus membrane; A method for deliverin...

Dosage: SUSPENSION/DROPS

More Information on Dosage

EYSUVIS family patents

Family Patents

48. Fetroja patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9238657 SHIONOGI INC Cephalosporin having catechol group
Nov, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-844) Sep 25, 2023
New Chemical Entity Exclusivity(NCE) Nov 14, 2024
Generating Antibiotic Incentives Now(GAIN) Nov 14, 2029

Drugs and Companies using CEFIDEROCOL SULFATE TOSYLATE ingredient

NCE-1 date: 14 November, 2028

Market Authorisation Date: 14 November, 2019

Treatment: Method of treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp) comprising administering cefiderocol sulfate tosylate

Dosage: POWDER

More Information on Dosage

FETROJA family patents

Family Patents

49. Fintepla patent expiration

FINTEPLA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10478442 UCB INC Method for the treatment of Dravet Syndrome
May, 2033

(8 years from now)

US12097206 UCB INC Method for the treatment of Dravet Syndrome
May, 2033

(8 years from now)

US9610260 UCB INC Method for the treatment of Dravet Syndrome
May, 2033

(8 years from now)

US9549909 UCB INC Method for the treatment of dravet syndrome
May, 2033

(8 years from now)

US9603815 UCB INC Method for the treatment of Dravet syndrome
May, 2033

(8 years from now)

US10478441 UCB INC Method for the treatment of Dravet syndrome
May, 2033

(8 years from now)

US9603814 UCB INC Method for the treatment of Dravet syndrome
May, 2033

(8 years from now)

US9603814

(Pediatric)

UCB INC Method for the treatment of Dravet syndrome
Nov, 2033

(8 years from now)

US10478441

(Pediatric)

UCB INC Method for the treatment of Dravet syndrome
Nov, 2033

(8 years from now)

US12097206

(Pediatric)

UCB INC Method for the treatment of Dravet Syndrome
Nov, 2033

(8 years from now)

US9610260

(Pediatric)

UCB INC Method for the treatment of Dravet Syndrome
Nov, 2033

(8 years from now)

US10478442

(Pediatric)

UCB INC Method for the treatment of Dravet Syndrome
Nov, 2033

(8 years from now)

US9603815

(Pediatric)

UCB INC Method for the treatment of Dravet syndrome
Nov, 2033

(8 years from now)

US9549909

(Pediatric)

UCB INC Method for the treatment of dravet syndrome
Nov, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 25, 2023
New Indication(I-887) Mar 25, 2025
Orphan Drug Exclusivity(ODE-312) Jun 25, 2027
Orphan Drug Exclusivity(ODE-393) Mar 25, 2029
Pediatric Exclusivity(PED) Sep 25, 2029

Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 25 June, 2020

Treatment: Use in combination with stiripentol for the treatment of seizures associated with dravet syndrome; A method of adjunctive treating, preventing and/or ameliorating seizures in a person with dravet synd...

Dosage: SOLUTION

How can I launch a generic of FINTEPLA before it's drug patent expiration?
More Information on Dosage

FINTEPLA family patents

Family Patents

50. Genvoya patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9296769

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(8 years from now)

US8754065

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(8 years from now)

US10039718

(Pediatric)

GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Apr, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Sep 25, 2020
New Chemical Entity Exclusivity(NCE) Nov 05, 2020
New Dosing Schedule(D-173) Dec 10, 2021

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 05 November, 2015

Treatment: NA

Dosage: TABLET

How can I launch a generic of GENVOYA before it's drug patent expiration?
More Information on Dosage

GENVOYA family patents

Family Patents

51. Givlaari patent expiration

Can you believe GIVLAARI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10125364 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Mar, 2033

(8 years from now)

US9133461 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Nov, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9631193 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Mar, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 20, 2024
Orphan Drug Exclusivity(ODE-273) Nov 20, 2026

Drugs and Companies using GIVOSIRAN SODIUM ingredient

NCE-1 date: 21 November, 2023

Market Authorisation Date: 20 November, 2019

Treatment: Treatment of acute hepatic porphyria

Dosage: SOLUTION

More Information on Dosage

GIVLAARI family patents

Family Patents

52. Harvoni patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9393256

(Pediatric)

GILEAD SCIENCES INC Methods for treating HCV
Mar, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-153) Nov 12, 2018
New Indication(I-718) Nov 12, 2018
New Indication(I-719) Nov 12, 2018
New Indication(I-720) Nov 12, 2018
New Dosing Schedule(D-158) Feb 12, 2019
New Dosing Schedule(D-159) Feb 12, 2019
New Dosing Schedule(D-160) Feb 12, 2019
New Chemical Entity Exclusivity(NCE) Oct 10, 2019
New Patient Population(NPP) Apr 07, 2020
New Dosing Schedule(D-177) Nov 15, 2022
Orphan Drug Exclusivity(ODE) Apr 07, 2024
ODE*(ODE*) Aug 28, 2026
Orphan Drug Exclusivity(ODE-136) Apr 07, 2024
Pediatric Exclusivity(PED) Oct 07, 2024
Orphan Drug Exclusivity(ODE-262) Aug 28, 2026
Orphan Drug Exclusivity(ODE-263) Aug 28, 2026
Orphan Drug Exclusivity(ODE-264) Aug 28, 2026

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

Market Authorisation Date: 28 August, 2019

Treatment: NA

Dosage: PELLETS; TABLET

More Information on Dosage

HARVONI family patents

Family Patents

53. Hepzato patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10195334 DELCATH SYSTEMS INC Filter and frame apparatus and method of use
Jan, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 14, 2026
Orphan Drug Exclusivity(ODE-438) Aug 14, 2030

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Market Authorisation Date: 14 August, 2023

Treatment: NA

Dosage: POWDER

More Information on Dosage

HEPZATO family patents

Family Patents

54. Hetlioz patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11850229 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11833130 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10980770 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11918557 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11826339 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11285129 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10610510 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9549913 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US8785492 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10945988 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10449176 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10149829 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9060995 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9539234 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

USRE46604 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9855241 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11633377 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11918556 VANDA PHARMS INC Treatment of circadian rhythm disorders
Apr, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 31, 2019
Orphan Drug Exclusivity(ODE) Jan 31, 2021
Orphan Drug Exclusivity(ODE-59) Jan 31, 2021
New Indication(I-850) Dec 01, 2023
Orphan Drug Exclusivity(ODE-330) Dec 01, 2027

Drugs and Companies using TASIMELTEON ingredient

NCE-1 date: 31 January, 2018

Market Authorisation Date: 31 January, 2014

Treatment: Treatment of non-24-hour sleep-wake disorder by avoiding the administration of tasimelteon with beta-adrenergic receptor antagonists; Treatment of nighttime sleep disturbances in smith-magenis syndrom...

Dosage: CAPSULE

How can I launch a generic of HETLIOZ before it's drug patent expiration?
More Information on Dosage

HETLIOZ family patents

Family Patents

55. Hetlioz Lq patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11285129 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11826339 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11918557 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11833130 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11850229 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10610510 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9539234 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10149829 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11633377 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10980770 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11918556 VANDA PHARMS INC Treatment of circadian rhythm disorders
Apr, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 01, 2023
Orphan Drug Exclusivity(ODE-329) Dec 01, 2027

Drugs and Companies using TASIMELTEON ingredient

Market Authorisation Date: 01 December, 2020

Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with beta-adrenergic receptor antagonists; Treatment of nighttime sleep disturbances i...

Dosage: SUSPENSION

More Information on Dosage

HETLIOZ LQ family patents

Family Patents

56. Ibsrela patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8541448 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Aug, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 12, 2024

Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient

NCE-1 date: 13 September, 2023

Market Authorisation Date: 12 September, 2019

Treatment: NA

Dosage: TABLET

More Information on Dosage

IBSRELA family patents

Family Patents

57. Iclusig patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11192897 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(8 years from now)

US11384086 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(8 years from now)

US9493470 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11192895 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 14, 2017
Orphan Drug Exclusivity(ODE) Dec 14, 2019
Orphan Drug Exclusivity(ODE-35) Dec 14, 2019
New Indication(I-849) Dec 18, 2023
New Indication(I-934) Mar 19, 2027
Orphan Drug Exclusivity(ODE-472) Mar 19, 2031

Drugs and Companies using PONATINIB HYDROCHLORIDE ingredient

NCE-1 date: 14 December, 2016

Market Authorisation Date: 18 December, 2020

Treatment: A method for treating chronic myeloid leukemia; A method for treating philadelphia chromosome positive acute lymphoblastic leukemia

Dosage: TABLET

How can I launch a generic of ICLUSIG before it's drug patent expiration?
More Information on Dosage

ICLUSIG family patents

Family Patents

58. Idhifa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9512107 BRISTOL MYERS SQUIBB Therapeutically active compositions and their methods of use
Jan, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10294215 BRISTOL MYERS SQUIBB Therapeutically active compounds and their methods of use
Jan, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 01, 2022
Orphan Drug Exclusivity(ODE) Aug 01, 2024
Orphan Drug Exclusivity(ODE-151) Aug 01, 2024

Drugs and Companies using ENASIDENIB MESYLATE ingredient

NCE-1 date: 01 August, 2021

Market Authorisation Date: 01 August, 2017

Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation

Dosage: TABLET

More Information on Dosage

IDHIFA family patents

Family Patents

59. Imbruvica patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10125140 PHARMACYCLICS LLC Crystalline forms of a bruton's tyrosine kinase inhibitor
Jun, 2033

(8 years from now)

US9725455 PHARMACYCLICS LLC Crystalline forms of a bruton's tyrosine kinase inhibitor
Jun, 2033

(8 years from now)

US10106548 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(8 years from now)

US9296753 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Oct, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10294232 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(8 years from now)

US9713617 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(8 years from now)

US10961251 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(8 years from now)

US10294231 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(8 years from now)

US10752634 PHARMACYCLICS LLC Crystalline forms of a brutons tyrosine kinase inhibitor
Jun, 2033

(8 years from now)

US9540382 PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Aug, 2033

(8 years from now)

US10106548

(Pediatric)

PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Dec, 2033

(8 years from now)

US9725455

(Pediatric)

PHARMACYCLICS LLC Crystalline forms of a bruton's tyrosine kinase inhibitor
Dec, 2033

(8 years from now)

US10125140

(Pediatric)

PHARMACYCLICS LLC Crystalline forms of a bruton's tyrosine kinase inhibitor
Dec, 2033

(8 years from now)

US10752634

(Pediatric)

PHARMACYCLICS LLC Crystalline forms of a brutons tyrosine kinase inhibitor
Dec, 2033

(8 years from now)

US10961251

(Pediatric)

PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Dec, 2033

(8 years from now)

US10294232

(Pediatric)

PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Dec, 2033

(8 years from now)

US9713617

(Pediatric)

PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Dec, 2033

(8 years from now)

US10294231

(Pediatric)

PHARMACYCLICS LLC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Dec, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-680) Feb 12, 2017
New Indication(I-689) Jul 28, 2017
New Indication(I-702) Jan 29, 2018
New Chemical Entity Exclusivity(NCE) Nov 13, 2018
New Indication(I-729) Mar 04, 2019
New Dosing Schedule(D-165) May 06, 2019
New Indication(I-736) May 06, 2019
New Indication(I-737) May 06, 2019
New Indication(I-741) Jan 18, 2020
New Indication(I-753) Aug 02, 2020
Orphan Drug Exclusivity(ODE-55) Nov 13, 2020
Orphan Drug Exclusivity(ODE-60) Feb 12, 2021
Orphan Drug Exclusivity(ODE-72) Jul 28, 2021
New Dosing Schedule(D-176) Aug 24, 2021
M(M-236) Jan 25, 2022
Orphan Drug Exclusivity(ODE-86) Jan 29, 2022
Orphan Drug Exclusivity(ODE-109) Mar 04, 2023
Orphan Drug Exclusivity(ODE-117) May 06, 2023
Orphan Drug Exclusivity(ODE-128) Jan 18, 2024
Orphan Drug Exclusivity(ODE) Aug 02, 2024
ODE*(ODE*) Aug 02, 2024
Orphan Drug Exclusivity(ODE-152) Aug 02, 2024
M(M-14) Aug 24, 2025
New Product(NP) Aug 24, 2025
New Patient Population(NPP) Aug 24, 2025
Pediatric Exclusivity(PED) Feb 24, 2026
Orphan Drug Exclusivity(ODE-405) Aug 24, 2029

Drugs and Companies using IBRUTINIB ingredient

NCE-1 date: 24 February, 2025

Market Authorisation Date: 20 December, 2017

Treatment: Treatment of mantle cell lymphoma

Dosage: CAPSULE; TABLET; SUSPENSION

How can I launch a generic of IMBRUVICA before it's drug patent expiration?
More Information on Dosage

IMBRUVICA family patents

Family Patents

60. Imvexxy patent expiration

IMVEXXY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10568891 MAYNE PHARMA Vaginal inserted estradiol pharmaceutical compositions and methods
Jun, 2033

(8 years from now)

US10668082 MAYNE PHARMA Vaginal inserted estradiol pharmaceutical compositions and methods
Jun, 2033

(8 years from now)

US10471072 MAYNE PHARMA Vaginal inserted estradiol pharmaceutical compositions and methods
Jun, 2033

(8 years from now)

US10888516 MAYNE PHARMA Soluble estradiol capsule for vaginal insertion
Jun, 2033

(8 years from now)

US11123283 MAYNE PHARMA Soluble estradiol capsule for vaginal insertion
Jun, 2033

(8 years from now)

US11116717 MAYNE PHARMA Soluble estradiol capsule for vaginal insertion
Jun, 2033

(8 years from now)

US11065197 MAYNE PHARMA Soluble estradiol capsule for vaginal insertion
Jun, 2033

(8 years from now)

US9180091 MAYNE PHARMA Soluble estradiol capsule for vaginal insertion
Dec, 2033

(8 years from now)

US10258630 MAYNE PHARMA Vaginal inserted estradiol pharmaceutical compositions and methods
Dec, 2033

(8 years from now)

US10398708 MAYNE PHARMA Vaginal inserted estradiol pharmaceutical compositions and methods
Dec, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 29, 2021

Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 29 May, 2018

Treatment: Treatment of a symptom of vulvar and vaginal atrophy; Treatment of dyspareunia; Treatment of moderate to severe dyspareunia

Dosage: INSERT

How can I launch a generic of IMVEXXY before it's drug patent expiration?
More Information on Dosage

IMVEXXY family patents

Family Patents

61. Infugem patent expiration

INFUGEM's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9241948 SUN PHARM Ready to be infused gemcetabine solution
Jul, 2033

(8 years from now)




Drugs and Companies using GEMCITABINE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 July, 2018

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

INFUGEM family patents

Family Patents

62. Inveltys patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11642317 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(8 years from now)

US11219597 ALCON LABS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(8 years from now)

US9056057 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(8 years from now)

US10688045 ALCON LABS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(8 years from now)

US9827191 ALCON LABS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(8 years from now)

US11872318 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(8 years from now)

US9737491 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(8 years from now)

US10058511 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(8 years from now)

US9532955 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(8 years from now)

US10646437 ALCON LABS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(8 years from now)

US10864219 ALCON LABS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(8 years from now)

US9393213 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 22, 2021

Drugs and Companies using LOTEPREDNOL ETABONATE ingredient

Market Authorisation Date: 22 August, 2018

Treatment: A method of treating postoperative inflammation following ocular surgery; A method for delivering a composition to a mucus membrane; A method for treating inflammation and/or other disorders in an eye...

Dosage: SUSPENSION/DROPS

More Information on Dosage

INVELTYS family patents

Family Patents

63. Ionsys patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9095706 THE MEDICINES CO Self-test for analgesic product
Feb, 2033

(8 years from now)




Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient

Market Authorisation Date: 22 May, 2006

Treatment: NA

Dosage: SYSTEM

More Information on Dosage

IONSYS family patents

Family Patents

64. Jentadueto Xr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9555001 BOEHRINGER INGELHEIM Pharmaceutical composition and uses thereof
Mar, 2033

(8 years from now)

US9555001

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition and uses thereof
Sep, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-258) Jul 03, 2022
M(M-252) Mar 30, 2023
M(M-295) Jun 20, 2026
Pediatric Exclusivity(PED) Dec 20, 2026

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 May, 2016

Treatment: Method of treating type 2 diabetes in patients with insufficient glycemic control despite therapy with one or more conventional antihyperglycemic agents by administering linagliptin in combination wit...

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of JENTADUETO XR before it's drug patent expiration?
More Information on Dosage

JENTADUETO XR family patents

Family Patents

65. Kalydeco patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8883206 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Feb, 2033

(8 years from now)

US11752106 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Feb, 2033

(8 years from now)

US10272046 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Feb, 2033

(8 years from now)

US11147770 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Feb, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 31, 2017
New Indication(I-740) Feb 21, 2017
New Indication(I-705) Dec 30, 2017
Orphan Drug Exclusivity(ODE) Jan 31, 2019
Orphan Drug Exclusivity(ODE-20) Jan 31, 2019
New Patient Population(NPP) May 03, 2026
Orphan Drug Exclusivity(ODE-186) Feb 21, 2021
Orphan Drug Exclusivity(ODE-187) Dec 29, 2021
Orphan Drug Exclusivity(ODE-188) Mar 17, 2022
Orphan Drug Exclusivity(ODE-190) May 17, 2024
Orphan Drug Exclusivity(ODE-189) Jul 31, 2024
Orphan Drug Exclusivity(ODE-199) Aug 15, 2025
Orphan Drug Exclusivity(ODE-236) Apr 29, 2026
Orphan Drug Exclusivity(ODE-338) Dec 21, 2027
Orphan Drug Exclusivity(ODE-435) May 03, 2030

Drugs and Companies using IVACAFTOR ingredient

NCE-1 date: 01 February, 2016

Market Authorisation Date: 03 May, 2023

Treatment: Treatment of cf in a patient age 1 month to <6 years who has at least one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition r...

Dosage: GRANULE

How can I launch a generic of KALYDECO before it's drug patent expiration?
More Information on Dosage

KALYDECO family patents

Family Patents

66. Kengreal patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8680052 CHIESI Methods of treating, reducing the incidence of, and/or preventing ischemic events
Mar, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 22, 2020

Drugs and Companies using CANGRELOR ingredient

NCE-1 date: 23 June, 2019

Market Authorisation Date: 22 June, 2015

Treatment: Method comprising iv administration of cangrelor before pci then continuous infusion for at least 2 hours or the duration of pci and, during or after continuous infusion, administration of a loading d...

Dosage: POWDER

How can I launch a generic of KENGREAL before it's drug patent expiration?
More Information on Dosage

KENGREAL family patents

Family Patents

67. Korlym patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10500216 CORCEPT THERAP Optimizing mifepristone absorption
Mar, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 17, 2015
Orphan Drug Exclusivity(ODE) Feb 17, 2019
Orphan Drug Exclusivity(ODE-22) Feb 17, 2019

Drugs and Companies using MIFEPRISTONE ingredient

Market Authorisation Date: 17 February, 2012

Treatment: Treating cushing's syndrome

Dosage: TABLET

How can I launch a generic of KORLYM before it's drug patent expiration?
More Information on Dosage

KORLYM family patents

Family Patents

68. Kuvan patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216178

(Pediatric)

BIOMARIN PHARM Dry blend formulation of tetrahydrobiopterin
May, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 13, 2012
Orphan Drug Exclusivity(ODE) Dec 13, 2014
New Patient Population(NPP) Apr 23, 2017
Pediatric Exclusivity(PED) Oct 23, 2017

Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient

Market Authorisation Date: 19 December, 2013

Treatment: NA

Dosage: POWDER

How can I launch a generic of KUVAN before it's drug patent expiration?
More Information on Dosage

KUVAN family patents

Family Patents

69. Kyprolis patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9493582 ONYX PHARMS AMGEN Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 20, 2017
New Indication(I-712) Jul 24, 2018
New Indication(I-722) Jan 21, 2019
New Indication(I-723) Jan 21, 2019
Orphan Drug Exclusivity(ODE) Jul 20, 2019
Orphan Drug Exclusivity(ODE-27) Jul 20, 2019
New Dosing Schedule(D-172) Sep 28, 2021
New Indication(I-842) Aug 20, 2023

Drugs and Companies using CARFILZOMIB ingredient

NCE-1 date: 20 July, 2016

Market Authorisation Date: 07 June, 2018

Treatment: NA

Dosage: POWDER

How can I launch a generic of KYPROLIS before it's drug patent expiration?
More Information on Dosage

KYPROLIS family patents

Family Patents

70. Kyzatrex patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11617758 MARIUS PHARMS LLC Emulsion formulations
Mar, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jul 27, 2025

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 27 July, 2022

Treatment: Method of treating testosterone deficiency

Dosage: CAPSULE

More Information on Dosage

KYZATREX family patents

Family Patents

71. Lantus Solostar patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9717852 SANOFI AVENTIS US Cartridge holder and pen-type injector
Apr, 2033

(8 years from now)




Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient

Market Authorisation Date: 27 April, 2007

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

LANTUS SOLOSTAR family patents

Family Patents

72. Liletta patent expiration

LILETTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US12004992 MEDICINES360 Kits for intrauterine systems and IUD insertion devices
Oct, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11090186 MEDICINES360 Methods for using intrauterine systems and IUD insertion devices
Oct, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 26, 2018
New Indication(I-917) Jun 29, 2026

Drugs and Companies using LEVONORGESTREL ingredient

Market Authorisation Date: 26 February, 2015

Treatment: A method for prevention of pregnancy

Dosage: SYSTEM

More Information on Dosage

LILETTA family patents

Family Patents

73. Linzess patent expiration

LINZESS's oppositions filed in EPO
Can you believe LINZESS received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9708371 ABBVIE Treatments for gastrointestinal disorders
Aug, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 30, 2017
New Strength(NS) Jan 25, 2020
New Indication(I-921) Jun 12, 2026

Drugs and Companies using LINACLOTIDE ingredient

NCE-1 date: 30 August, 2016

Market Authorisation Date: 25 January, 2017

Treatment: Treatment of functional constipation in pediatric patients 6 to 17 years of age

Dosage: CAPSULE

How can I launch a generic of LINZESS before it's drug patent expiration?
More Information on Dosage

LINZESS family patents

Family Patents

74. Liposyn Iii 30% patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9717852 HOSPIRA Cartridge holder and pen-type injector
Apr, 2033

(8 years from now)




Drugs and Companies using SOYBEAN OIL ingredient

Market Authorisation Date: 13 January, 1998

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

LIPOSYN III 30% family patents

Family Patents

75. Lodoco patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11026899 AGEPHA PHARMA FZ Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
Nov, 2033

(8 years from now)

US11026900 AGEPHA PHARMA FZ Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
Nov, 2033

(8 years from now)

US11026901 AGEPHA PHARMA FZ Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
Nov, 2033

(8 years from now)

US10206891 AGEPHA PHARMA FZ Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent
Nov, 2033

(8 years from now)

US10842762 AGEPHA PHARMA FZ Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent
Nov, 2033

(8 years from now)

US9744144 AGEPHA PHARMA FZ Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent
Nov, 2033

(8 years from now)

US11944594 AGEPHA PHARMA FZ Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
Nov, 2033

(8 years from now)

US10265281 AGEPHA PHARMA FZ Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
Nov, 2033

(8 years from now)

US11944595 AGEPHA PHARMA FZ Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
Nov, 2033

(8 years from now)




Drugs and Companies using COLCHICINE ingredient

Market Authorisation Date: 16 June, 2023

Treatment: A method for treating and/or reducing the risk of a cardiovascular event; A method for treating and/or reducing the risk of acute myocardial infarction; A method of treating and/or reducing the risk o...

Dosage: TABLET

More Information on Dosage

LODOCO family patents

Family Patents

76. Lokelma patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10695365 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Oct, 2033

(8 years from now)

US9913860 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Oct, 2033

(8 years from now)

US8877255 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Oct, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-261) Apr 24, 2023
New Chemical Entity Exclusivity(NCE) May 18, 2023

Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient

NCE-1 date: 18 May, 2022

Market Authorisation Date: 18 May, 2018

Treatment: Treatment of hyperkalemia in adults

Dosage: FOR SUSPENSION

How can I launch a generic of LOKELMA before it's drug patent expiration?
More Information on Dosage

LOKELMA family patents

Family Patents

77. Lonhala Magnair Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9604018 SUMITOMO PHARMA AM Aerosol therapy device
May, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 05, 2020

Drugs and Companies using GLYCOPYRROLATE ingredient

Market Authorisation Date: 05 December, 2017

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

LONHALA MAGNAIR KIT family patents

Family Patents

78. Lorbrena patent expiration

Can you believe LORBRENA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8680111 PFIZER Macrocyclic derivatives for the treatment of diseases
Mar, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 02, 2023
New Indication(I-847) Mar 03, 2024
Orphan Drug Exclusivity(ODE-217) Nov 02, 2025
Orphan Drug Exclusivity(ODE-218) Nov 02, 2025
Orphan Drug Exclusivity(ODE-219) Nov 02, 2025
Orphan Drug Exclusivity(ODE-349) Mar 03, 2028

Drugs and Companies using LORLATINIB ingredient

NCE-1 date: 02 November, 2022

Market Authorisation Date: 02 November, 2018

Treatment: NA

Dosage: TABLET

More Information on Dosage

LORBRENA family patents

Family Patents

79. Luzu patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9453006 BAUSCH Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient
Sep, 2033

(8 years from now)

US9012484 BAUSCH Crystal and pharmaceutical preparation containing the same crystal
Sep, 2033

(8 years from now)

US9199977 BAUSCH Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal
Sep, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 14, 2018
New Patient Population(NPP) Feb 20, 2021

Drugs and Companies using LULICONAZOLE ingredient

NCE-1 date: 14 November, 2017

Market Authorisation Date: 14 November, 2013

Treatment: Treatment of fungal infections

Dosage: CREAM

More Information on Dosage

LUZU family patents

Family Patents

80. Lytgobi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9108973 TAIHO ONCOLOGY 3,5-disubstituted alkynylbenzene compound and salt thereof
Feb, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 30, 2027
Orphan Drug Exclusivity(ODE-410) Sep 30, 2029

Drugs and Companies using FUTIBATINIB ingredient

NCE-1 date: 30 September, 2026

Market Authorisation Date: 30 September, 2022

Treatment: Method of treating intrahepatic cholangiocarcinoma

Dosage: TABLET

More Information on Dosage

LYTGOBI family patents

Family Patents

81. Mekinist patent expiration

MEKINIST's oppositions filed in EPO
Can you believe MEKINIST received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10869869 NOVARTIS Method of adjuvant cancer treatment
Aug, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-678) Jan 08, 2017
New Chemical Entity Exclusivity(NCE) May 29, 2018
M(M-170) Nov 20, 2018
Orphan Drug Exclusivity(ODE) May 29, 2020
Orphan Drug Exclusivity(ODE-48) May 29, 2020
New Indication(I-745) Jun 22, 2020
Orphan Drug Exclusivity(ODE-57) Jan 08, 2021
New Indication(I-778) Apr 30, 2021
New Indication(I-781) May 04, 2021
M(M-246) Oct 06, 2022
Orphan Drug Exclusivity(ODE-148) Jun 22, 2024
Orphan Drug Exclusivity(ODE-182) Apr 30, 2025
Orphan Drug Exclusivity(ODE-183) May 04, 2025
New Indication(I-895) Jun 22, 2025
Pediatric Exclusivity(PED) Sep 16, 2026
New Indication(I-908) Mar 16, 2026
New Product(NP) Mar 16, 2026
Orphan Drug Exclusivity(ODE-428) Mar 16, 2030

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

NCE-1 date: 22 December, 2024

Market Authorisation Date: 29 May, 2013

Treatment: Mekinist(r) is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement o...

Dosage: TABLET

More Information on Dosage

MEKINIST family patents

Family Patents

82. Mektovi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9562016 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor
Oct, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9980944 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor
Oct, 2033

(8 years from now)

US9598376 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor
Oct, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 27, 2023
Orphan Drug Exclusivity(ODE-194) Jun 27, 2025
New Indication(I-928) Oct 11, 2026

Drugs and Companies using BINIMETINIB ingredient

NCE-1 date: 27 June, 2022

Market Authorisation Date: 27 June, 2018

Treatment: Treatment of melanoma with a braf mutation; Method of treating melanoma

Dosage: TABLET

How can I launch a generic of MEKTOVI before it's drug patent expiration?
More Information on Dosage

MEKTOVI family patents

Family Patents

83. Miebo patent expiration

MIEBO IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10058615 BAUSCH AND LOMB INC Semifluorinated alkane compositions
Sep, 2033

(8 years from now)

US10449164 BAUSCH AND LOMB INC Methods of treating ocular disorders using semifluorinated alkanes
Sep, 2033

(8 years from now)

US10369117 BAUSCH AND LOMB INC Compositions comprising mixtures of semifluorinated alkanes
Sep, 2033

(8 years from now)

US10576154 BAUSCH AND LOMB INC Semifluorinated alkane compositions
Sep, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 18, 2028

Drugs and Companies using PERFLUOROHEXYLOCTANE ingredient

NCE-1 date: 19 May, 2027

Market Authorisation Date: 18 May, 2023

Treatment: Treatment of the signs and symptoms of dry eye disease (ded)

Dosage: SOLUTION/DROPS

More Information on Dosage

MIEBO family patents

Family Patents

84. Mitigare patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9399036 HIKMA INTL PHARMS Methods of colchicine administration
Aug, 2033

(8 years from now)

US9789108 HIKMA INTL PHARMS Methods of colchicine administration
Aug, 2033

(8 years from now)

US9555029 HIKMA INTL PHARMS Methods of colchicine administration
Aug, 2033

(8 years from now)

US9675613 HIKMA INTL PHARMS Methods of colchicine administration
Aug, 2033

(8 years from now)

US8927607 HIKMA INTL PHARMS Methods of colchicine administration
Aug, 2033

(8 years from now)




Drugs and Companies using COLCHICINE ingredient

Market Authorisation Date: 26 September, 2014

Treatment: Method of using colchicine for the prophylaxis of gout flares

Dosage: CAPSULE

How can I launch a generic of MITIGARE before it's drug patent expiration?
More Information on Dosage

MITIGARE family patents

Family Patents

85. Myfembree patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11795178 SUMITOMO PHARMA Compositions of thienopyrimidine derivatives
Sep, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 26, 2024
New Indication(I-898) Aug 05, 2025
New Chemical Entity Exclusivity(NCE) Dec 18, 2025
M(M-289) Jan 27, 2026

Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient

NCE-1 date: 18 December, 2024

Market Authorisation Date: 26 May, 2021

Treatment: NA

Dosage: TABLET

More Information on Dosage

MYFEMBREE family patents

Family Patents

86. Naftin patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9161914 SEBELA IRELAND LTD Topical compositions and methods for making and using same
Jan, 2033

(8 years from now)

US10166205 SEBELA IRELAND LTD Topical compositions and methods for making and using same
Jan, 2033

(8 years from now)

US8778365 SEBELA IRELAND LTD Topical compositions and methods for making and using same
Jan, 2033

(8 years from now)

US10729667 SEBELA IRELAND LTD Topical compositions and methods for making and using same
Jan, 2033

(8 years from now)

US10166206 SEBELA IRELAND LTD Topical compositions and methods for making and using same
Jan, 2033

(8 years from now)

US10695303 SEBELA IRELAND LTD Topical compositions and methods for making and using same
Jan, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Strength(NS) Jan 13, 2015
New Product(NP) Jun 27, 2016
M(M-191) Nov 10, 2019

Drugs and Companies using NAFTIFINE HYDROCHLORIDE ingredient

Market Authorisation Date: 27 June, 2013

Treatment: Treatment of fungal infections

Dosage: GEL

How can I launch a generic of NAFTIN before it's drug patent expiration?
More Information on Dosage

NAFTIN family patents

Family Patents

87. Natroba patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9895388 CIPHER Methods and compositions useful for controlling cutaneous mites
Nov, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 18, 2016
M(M-152) Nov 30, 2017
New Indication(I-858) Apr 28, 2024

Drugs and Companies using SPINOSAD ingredient

NCE-1 date: 18 January, 2015

Market Authorisation Date: 18 January, 2011

Treatment: The product composition (natroba) is for the topical treatment of human scabies mite infestations by melting and delivering the active ingredient, spinosad, to the stratum corneum where scabies mites ...

Dosage: SUSPENSION

More Information on Dosage

NATROBA family patents

Family Patents

88. Noxafil patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9493582 MERCK SHARP DOHME Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 15, 2011
New Patient Population(NPP) May 31, 2024
New Indication(I-881) Jun 17, 2024
Orphan Drug Exclusivity(ODE-355) Jun 17, 2028

Drugs and Companies using POSACONAZOLE ingredient

Market Authorisation Date: 13 March, 2014

Treatment: NA

Dosage: SOLUTION

How can I launch a generic of NOXAFIL before it's drug patent expiration?
More Information on Dosage

NOXAFIL family patents

Family Patents

89. Nubeqa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8975254 BAYER HEALTHCARE Androgen receptor modulating compounds
Mar, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 30, 2024
New Indication(I-900) Aug 05, 2025

Drugs and Companies using DAROLUTAMIDE ingredient

NCE-1 date: 31 July, 2023

Market Authorisation Date: 30 July, 2019

Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer

Dosage: TABLET

More Information on Dosage

NUBEQA family patents

Family Patents

90. Nurtec Odt patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8759372 PFIZER N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt
Feb, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-865) May 27, 2024
New Chemical Entity Exclusivity(NCE) Feb 27, 2025

Drugs and Companies using RIMEGEPANT SULFATE ingredient

NCE-1 date: 28 February, 2024

Market Authorisation Date: 27 February, 2020

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING

More Information on Dosage

NURTEC ODT family patents

Family Patents

91. Ocaliva patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10174073 INTERCEPT PHARMS INC Preparation and uses of obeticholic acid
Jun, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238673 INTERCEPT PHARMS INC Preparation and uses of obeticholic acid
Jun, 2033

(8 years from now)

US10047117 INTERCEPT PHARMS INC Preparation and uses of obeticholic acid
Sep, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 27, 2021
Orphan Drug Exclusivity(ODE) May 27, 2023
Orphan Drug Exclusivity(ODE-119) May 27, 2023

Drugs and Companies using OBETICHOLIC ACID ingredient

NCE-1 date: 27 May, 2020

Market Authorisation Date: 27 May, 2016

Treatment: Treatment of primary biliary cholangitis (pbc)

Dosage: TABLET

How can I launch a generic of OCALIVA before it's drug patent expiration?
More Information on Dosage

OCALIVA family patents

Family Patents

92. Odefsey patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8754065

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(8 years from now)

US9296769

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-206) Aug 21, 2020
M(M-207) Aug 21, 2020
New Chemical Entity Exclusivity(NCE) Nov 05, 2020

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 01 March, 2016

Treatment: NA

Dosage: TABLET

How can I launch a generic of ODEFSEY before it's drug patent expiration?
More Information on Dosage

ODEFSEY family patents

Family Patents

93. Omidria patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9066856 RAYNER SURGICAL Stable preservative-free mydriatic and anti-inflammatory solutions for injection
Oct, 2033

(8 years from now)

US9855246 RAYNER SURGICAL Stable preservative-free mydriatic and anti-inflammatory solutions for injection
Oct, 2033

(8 years from now)

US9486406 RAYNER SURGICAL Stable preservative-free mydriatic and anti-inflammatory solutions for injection
Oct, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 30, 2017
New Patient Population(NPP) Dec 08, 2020
Pediatric Exclusivity(PED) Jun 08, 2021

Drugs and Companies using KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 May, 2014

Treatment: NA

Dosage: SOLUTION

How can I launch a generic of OMIDRIA before it's drug patent expiration?
More Information on Dosage

OMIDRIA family patents

Family Patents

94. Onivyde patent expiration

ONIVYDE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9452162 IPSEN Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Jun, 2033

(8 years from now)

US11369597 IPSEN Methods for treating pancreatic cancer using combination therapies
Jun, 2033

(8 years from now)

US9339497 IPSEN Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Jun, 2033

(8 years from now)

US9492442 IPSEN Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Jun, 2033

(8 years from now)

US9717724 IPSEN Methods for treating pancreatic cancer using combination therapies
Jun, 2033

(8 years from now)

US10980795 IPSEN Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Jun, 2033

(8 years from now)

US9364473 IPSEN Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Jun, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 22, 2018
Orphan Drug Exclusivity(ODE) Oct 22, 2022
Orphan Drug Exclusivity(ODE-99) Oct 22, 2022
New Indication(I-932) Feb 13, 2027
Orphan Drug Exclusivity(ODE-463) Feb 13, 2031

Drugs and Companies using IRINOTECAN HYDROCHLORIDE ingredient

Market Authorisation Date: 22 October, 2015

Treatment: Treatment of pancreatic cancer that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; Treatment of metastatic adenocarcinoma of the pancreas that has prog...

Dosage: INJECTABLE, LIPOSOMAL

More Information on Dosage

ONIVYDE family patents

Family Patents

95. Onzetra Xsail patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10478574 CURRAX Nasal administration
Nov, 2033

(8 years from now)




Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 27 January, 2016

Treatment: Method of delivering sumatriptan to a nasal cavity

Dosage: POWDER

More Information on Dosage

ONZETRA XSAIL family patents

Family Patents

96. Opfolda patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10512677 AMICUS THERAP US High concentration alpha-glucosidase compositions for the treatment of pompe disease
Mar, 2033

(8 years from now)

US11278599 AMICUS THERAP US High concentration alpha-glucosidase compositions for the treatment of Pompe disease
Mar, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 28, 2026

Drugs and Companies using MIGLUSTAT ingredient

Market Authorisation Date: 28 September, 2023

Treatment: The treatment of pompe patients

Dosage: CAPSULE

More Information on Dosage

OPFOLDA family patents

Family Patents

97. Orfadin patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9301932 SWEDISH ORPHAN Liquid pharmaceutical composition comprising nitisinone
Feb, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-169) Sep 01, 2020

Drugs and Companies using NITISINONE ingredient

Market Authorisation Date: 22 April, 2016

Treatment: Treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine

Dosage: SUSPENSION

More Information on Dosage

ORFADIN family patents

Family Patents

98. Orgovyx patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11795178 SUMITOMO PHARMA Compositions of thienopyrimidine derivatives
Sep, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 18, 2025

Drugs and Companies using RELUGOLIX ingredient

NCE-1 date: 18 December, 2024

Market Authorisation Date: 18 December, 2020

Treatment: NA

Dosage: TABLET

More Information on Dosage

ORGOVYX family patents

Family Patents

99. Oxbryta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9018210 GLOBAL BLOOD THERAPS Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Nov, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 25, 2024
Orphan Drug Exclusivity(ODE-281) Nov 25, 2026
Orphan Drug Exclusivity(ODE-394) Dec 17, 2028

Drugs and Companies using VOXELOTOR ingredient

NCE-1 date: 26 November, 2023

Market Authorisation Date: 14 October, 2022

Treatment: NA

Dosage: TABLET, FOR SUSPENSION; TABLET

More Information on Dosage

OXBRYTA family patents

Family Patents

100. Ozempic patent expiration

What is Ozempic?

Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.

What is the Ozempic controversy?

The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.

OZEMPIC's oppositions filed in EPO
OZEMPIC IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10335462 NOVO Use of long-acting GLP-1 peptides
Jun, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 05, 2022
New Indication(I-822) Jan 16, 2023
New Dosing Schedule(D-185) Mar 28, 2025

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: 05 December, 2021

Market Authorisation Date: 05 December, 2017

Treatment: A method of treating type 2 diabetes comprising administering semaglutide once weekly in a amount of 1.0 mg to a subject in need thereof

Dosage: SOLUTION

How can I launch a generic of OZEMPIC before it's drug patent expiration?
More Information on Dosage

OZEMPIC family patents

Family Patents

101. Pemazyre patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10131667 INCYTE CORP Substituted tricyclic compounds as FGFR inhibitors
Jun, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 17, 2025
New Indication(I-899) Aug 26, 2025
Orphan Drug Exclusivity(ODE-292) Apr 17, 2027
Orphan Drug Exclusivity(ODE-404) Aug 26, 2029

Drugs and Companies using PEMIGATINIB ingredient

NCE-1 date: 17 April, 2024

Market Authorisation Date: 17 April, 2020

Treatment: For the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement

Dosage: TABLET

More Information on Dosage

PEMAZYRE family patents

Family Patents

102. Phenylephrine Hydrochloride patent expiration

PHENYLEPHRINE HYDROCHLORIDE IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8859623 PARAGON BIOTECK Methods and compositions of stable phenylephrine formulations
Nov, 2033

(8 years from now)




Drugs and Companies using PHENYLEPHRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 March, 2013

Treatment: Dilation of the pupil

Dosage: SOLUTION/DROPS

More Information on Dosage

PHENYLEPHRINE HYDROCHLORIDE family patents

Family Patents

103. Phexxi patent expiration

Can you believe PHEXXI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11439610 EVOFEM INC Compositions and methods for enhancing the efficacy of contraceptive microbicides
Mar, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11337989 EVOFEM INC Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
Mar, 2033

(8 years from now)

US11992472 EVOFEM INC Compositions and methods for enhancing the efficacy of contraceptive microbicides
Mar, 2033

(8 years from now)

US10568855 EVOFEM INC Compositions and methods for enhancing the efficacy of contraceptive microbicides
Mar, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 22, 2023

Drugs and Companies using CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE ingredient

Market Authorisation Date: 22 May, 2020

Treatment: Prevention of pregnancy

Dosage: GEL

How can I launch a generic of PHEXXI before it's drug patent expiration?
More Information on Dosage

PHEXXI family patents

Family Patents

104. Picato patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9789078 LEO LABS Method of topically treating actinic keratosis with ingenol mebutate cycle therapy
May, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 23, 2017
M(M-169) Nov 19, 2018

Drugs and Companies using INGENOL MEBUTATE ingredient

NCE-1 date: 24 January, 2016

Market Authorisation Date: 23 January, 2012

Treatment: Topical treatment of actinic keratosis of the face or scalp using more than one treatment course of ingenol mebutate

Dosage: GEL

How can I launch a generic of PICATO before it's drug patent expiration?
More Information on Dosage

PICATO family patents

Family Patents

105. Piqray patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8227462 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Apr, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 24, 2024
New Indication(I-937) Jan 18, 2027

Drugs and Companies using ALPELISIB ingredient

NCE-1 date: 25 May, 2023

Market Authorisation Date: 24 May, 2019

Treatment: In combination with fulvestrant for treatment of adults with hr-positive, her-2-negative, pik3ca-mutated, advanced or metastatic breast cancer

Dosage: TABLET

More Information on Dosage

PIQRAY family patents

Family Patents

106. Plenvu patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8999313 SALIX Compositions
Sep, 2033

(8 years from now)

US9326969 SALIX Compositions
Sep, 2033

(8 years from now)

US10016504 SALIX Compositions
Sep, 2033

(8 years from now)

US9707297 SALIX Compositions
Sep, 2033

(8 years from now)

US10918723 SALIX Colon cleansing compositions and methods of use
Sep, 2033

(8 years from now)

US12083179 SALIX Colon cleansing compositions and method of use
Sep, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 04, 2021

Drugs and Companies using ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE ingredient

Market Authorisation Date: 04 May, 2018

Treatment: For cleansing of the colon in preparation for colonoscopy in adults

Dosage: FOR SOLUTION

How can I launch a generic of PLENVU before it's drug patent expiration?
More Information on Dosage

PLENVU family patents

Family Patents

107. Prevymis patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603384 MERCK SHARP DOHME Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
Feb, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 08, 2022
ODE*(ODE*) Jun 05, 2030
Orphan Drug Exclusivity(ODE-165) Nov 08, 2024
New Indication(I-916) Jun 05, 2026
New Dosing Schedule(D-189) Aug 02, 2026
New Product(NP) Aug 30, 2027
New Patient Population(NPP) Aug 30, 2027
Orphan Drug Exclusivity(ODE-423) Jun 05, 2030
Orphan Drug Exclusivity(ODE-495) Aug 30, 2031
Orphan Drug Exclusivity(ODE-497) Aug 30, 2031

Drugs and Companies using LETERMOVIR ingredient

NCE-1 date: 08 November, 2021

Market Authorisation Date: 08 November, 2017

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

PREVYMIS family patents

Family Patents

108. Prolensa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9517220 BAUSCH AND LOMB Bromfenac bioavailability
Nov, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 05, 2016

Drugs and Companies using BROMFENAC SODIUM ingredient

Market Authorisation Date: 05 April, 2013

Treatment: Treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery

Dosage: SOLUTION/DROPS

How can I launch a generic of PROLENSA before it's drug patent expiration?
More Information on Dosage

PROLENSA family patents

Family Patents

109. Pyrukynd patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11793806 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
Apr, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 17, 2027
Orphan Drug Exclusivity(ODE-392) Feb 17, 2029

Drugs and Companies using MITAPIVAT SULFATE ingredient

NCE-1 date: 17 February, 2026

Market Authorisation Date: 17 February, 2022

Treatment: Method for increasing the lifetime of red blood cells (rbcs) for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency

Dosage: TABLET

More Information on Dosage

PYRUKYND family patents

Family Patents

110. Qbrexza patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10548875 JOURNEY Glycopyrrolate salts
Feb, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9006462 JOURNEY Glycopyrrolate salts
Feb, 2033

(8 years from now)

US10004717 JOURNEY Glycopyrrolate salts
Feb, 2033

(8 years from now)

US8859610 JOURNEY Crystalline glycopyrrolate tosylate
Feb, 2033

(8 years from now)

US10543192 JOURNEY Glycopyrrolate salts
Feb, 2033

(8 years from now)

US9259414 JOURNEY Glycopyrrolate salts
Feb, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 28, 2021

Drugs and Companies using GLYCOPYRRONIUM TOSYLATE ingredient

Market Authorisation Date: 28 June, 2018

Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older

Dosage: CLOTH

How can I launch a generic of QBREXZA before it's drug patent expiration?
More Information on Dosage

QBREXZA family patents

Family Patents

111. Qelbree patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9662338 SUPERNUS PHARMS Formulations of viloxazine
Feb, 2033

(8 years from now)

US9358204 SUPERNUS PHARMS Formulations of viloxazine
Feb, 2033

(8 years from now)

US9603853 SUPERNUS PHARMS Formulations of viloxazine
Feb, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Apr 29, 2025
New Chemical Entity Exclusivity(NCE) Apr 02, 2026

Drugs and Companies using VILOXAZINE HYDROCHLORIDE ingredient

NCE-1 date: 02 April, 2025

Market Authorisation Date: 02 April, 2021

Treatment: For the treatment of attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE

More Information on Dosage

QELBREE family patents

Family Patents

112. Qudexy Xr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8652527 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(8 years from now)

US9101545 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(8 years from now)

US8889190 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(8 years from now)

US10363224 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(8 years from now)

US9555005 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(8 years from now)




Drugs and Companies using TOPIRAMATE ingredient

Market Authorisation Date: 11 March, 2014

Treatment: Treatment of seizures

Dosage: CAPSULE, EXTENDED RELEASE

How can I launch a generic of QUDEXY XR before it's drug patent expiration?
More Information on Dosage

QUDEXY XR family patents

Family Patents

113. Quillichew Er patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11633389 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet
Aug, 2033

(8 years from now)

US9545399 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet
Aug, 2033

(8 years from now)

US10857143 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet
Aug, 2033

(8 years from now)

US9844544 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet
Aug, 2033

(8 years from now)

US11103495 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet
Aug, 2033

(8 years from now)

US11103494 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet
Aug, 2033

(8 years from now)

US9295642 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet
Aug, 2033

(8 years from now)

US8999386 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet
Aug, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 04, 2018

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 04 December, 2015

Treatment: A method of providing a subject with therapeutically effective amount of racemic methylphenidate by orally administering to said subject a single methylphenidate extended release chewable tablet accor...

Dosage: TABLET, EXTENDED RELEASE, CHEWABLE

How can I launch a generic of QUILLICHEW ER before it's drug patent expiration?
More Information on Dosage

QUILLICHEW ER family patents

Family Patents

114. Qulipta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9850246 ABBVIE Process for making CGRP receptor antagonists
Mar, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-909) Apr 17, 2026
New Chemical Entity Exclusivity(NCE) Sep 28, 2026

Drugs and Companies using ATOGEPANT ingredient

NCE-1 date: 28 September, 2025

Market Authorisation Date: 28 September, 2021

Treatment: NA

Dosage: TABLET

More Information on Dosage

QULIPTA family patents

Family Patents

115. Quviviq patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9732075 IDORSIA Benzimidazole-proline derivatives
Jun, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 07, 2027
M(M-310) Sep 30, 2027

Drugs and Companies using DARIDOREXANT HYDROCHLORIDE ingredient

NCE-1 date: 07 April, 2026

Market Authorisation Date: 07 April, 2022

Treatment: Treatment of insomnia

Dosage: TABLET

More Information on Dosage

QUVIVIQ family patents

Family Patents

116. Recarbrio patent expiration

Can you believe RECARBRIO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8487093 MSD MERCK CO β-lactamase inhibitors
Mar, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 16, 2024
Generating Antibiotic Incentives Now(GAIN) Jul 16, 2029

Drugs and Companies using CILASTATIN SODIUM; IMIPENEM; RELEBACTAM ingredient

NCE-1 date: 16 July, 2028

Market Authorisation Date: 16 July, 2019

Treatment: Treatment of complicated urinary tract infections, including pyelonephritis (cuti)

Dosage: POWDER

More Information on Dosage

RECARBRIO family patents

Family Patents

117. Relyvrio patent expiration

RELYVRIO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10251896 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(9 years from now)

US9872865 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(9 years from now)

US10857162 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(9 years from now)

US11071742 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 29, 2027
Orphan Drug Exclusivity(ODE-411) Sep 29, 2029

Drugs and Companies using SODIUM PHENYLBUTYRATE; TAURURSODIOL ingredient

NCE-1 date: 29 September, 2026

Market Authorisation Date: 29 September, 2022

Treatment: Treatment of amyotrophic lateral sclerosis (als) in adults

Dosage: FOR SUSPENSION

More Information on Dosage

RELYVRIO family patents

Family Patents

118. Rexulti patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10307419

(Pediatric)

OTSUKA Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof
Apr, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-186) Sep 23, 2019
New Chemical Entity Exclusivity(NCE) Jul 10, 2020
New Patient Population(NPP) Dec 27, 2024
New Indication(I-913) May 10, 2026
Pediatric Exclusivity(PED) Nov 10, 2026
M(M-14) May 08, 2027

Drugs and Companies using BREXPIPRAZOLE ingredient

NCE-1 date: 10 November, 2025

Market Authorisation Date: 10 July, 2015

Treatment: NA

Dosage: TABLET

How can I launch a generic of REXULTI before it's drug patent expiration?
More Information on Dosage

REXULTI family patents

Family Patents

119. Rezdiffra patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9266861 MADRIGAL Method of synthesizing thyroid hormone analogs and polymorphs thereof
Sep, 2033

(8 years from now)

US11564926 MADRIGAL Methods of synthesizing thyroid hormone analogs and polymorphs thereof
Sep, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11986481 MADRIGAL Method of synthesizing thyroid hormone analogs and polymorphs thereof
Sep, 2033

(8 years from now)

US10376517 MADRIGAL Methods of synthesizing thyroid hormone analogs and polymorphs thereof
Sep, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 14, 2029

Drugs and Companies using RESMETIROM ingredient

NCE-1 date: 14 March, 2028

Market Authorisation Date: 14 March, 2024

Treatment: Treatment of adults with noncirrhotic nonalcoholic steatohepatitis (nash) with moderate to advanced liver fibrosis (consistent with stages f2 to f3 fibrosis)

Dosage: TABLET

More Information on Dosage

REZDIFFRA family patents

Family Patents

120. Rezurock patent expiration

REZUROCK's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10696660 KADMON PHARMS LLC Rho kinase inhibitors
Oct, 2033

(8 years from now)

US9815820 KADMON PHARMS LLC Rho kinase inhibitors
Oct, 2033

(8 years from now)

US10183931 KADMON PHARMS LLC Rho kinase inhibitors
Oct, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 16, 2026
Orphan Drug Exclusivity(ODE-362) Jul 16, 2028

Drugs and Companies using BELUMOSUDIL MESYLATE ingredient

NCE-1 date: 16 July, 2025

Market Authorisation Date: 16 July, 2021

Treatment: For the treatment of chronic graft versus host disease; For the treatment of chronic graft versus hold disease

Dosage: TABLET

More Information on Dosage

REZUROCK family patents

Family Patents

121. Rezzayo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9526835 MUNDIPHARMA Dosing regimens for echinocandin class compounds
Mar, 2033

(8 years from now)

US10702573 MUNDIPHARMA Dosing regimens for echinocandin class compounds
Mar, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 22, 2028
Orphan Drug Exclusivity(ODE-426) Mar 22, 2030
Generating Antibiotic Incentives Now(GAIN) Mar 22, 2033

Drugs and Companies using REZAFUNGIN ACETATE ingredient

NCE-1 date: 22 March, 2032

Market Authorisation Date: 22 March, 2023

Treatment: Treatment of candidemia and invasive candidiasis with rezafungin by intravenous administration

Dosage: POWDER

More Information on Dosage

REZZAYO family patents

Family Patents

122. Rinvoq patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE47221 ABBVIE Tricyclic compounds
Aug, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 16, 2024
New Indication(I-880) Dec 14, 2024
New Indication(I-883) Jan 14, 2025
New Indication(I-886) Mar 16, 2025
New Indication(I-888) Apr 29, 2025
New Indication(I-919) May 18, 2026
New Indication(I-946) Apr 26, 2027
New Patient Population(NPP) Apr 26, 2027
Orphan Drug Exclusivity(ODE-481) Apr 26, 2031

Drugs and Companies using UPADACITINIB ingredient

NCE-1 date: 17 August, 2023

Market Authorisation Date: 16 August, 2019

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

RINVOQ family patents

Family Patents

123. Rinvoq Lq patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE47221 ABBVIE Tricyclic compounds
Aug, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 16, 2024
New Product(NP) Apr 26, 2027
Orphan Drug Exclusivity(ODE-481) Apr 26, 2031

Drugs and Companies using UPADACITINIB ingredient

NCE-1 date: 17 August, 2023

Market Authorisation Date: 26 April, 2024

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

RINVOQ LQ family patents

Family Patents

124. Roszet patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9763885 ALTHERA PHARMS Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
May, 2033

(8 years from now)

US10376470 ALTHERA PHARMS Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
May, 2033

(8 years from now)




Drugs and Companies using EZETIMIBE; ROSUVASTATIN CALCIUM ingredient

Market Authorisation Date: 23 March, 2021

Treatment: Treatment of hyperlipidemia

Dosage: TABLET

More Information on Dosage

ROSZET family patents

Family Patents

125. Rozlytrek patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9085565 GENENTECH INC Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649306 GENENTECH INC Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 15, 2024
Orphan Drug Exclusivity(ODE-265) Aug 15, 2026
Orphan Drug Exclusivity(ODE-313) Aug 15, 2026
New Product(NP) Oct 20, 2026
New Patient Population(NPP) Oct 20, 2026
Orphan Drug Exclusivity(ODE-448) Oct 20, 2030

Drugs and Companies using ENTRECTINIB ingredient

NCE-1 date: 16 August, 2023

Market Authorisation Date: 15 August, 2019

Treatment: Treatment of ros1-positive non-small cell lung cancer

Dosage: CAPSULE

More Information on Dosage

ROZLYTREK family patents

Family Patents

126. Rybelsus patent expiration

RYBELSUS's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11759502 NOVO Compositions of GLP-1 peptides and preparation thereof
Mar, 2033

(8 years from now)

US10933120 NOVO Compositions of GLP-1 peptides and preparation thereof
Mar, 2033

(8 years from now)

US11759503 NOVO Compositions of GLP-1 peptides and preparation thereof
Mar, 2033

(8 years from now)

US11759501 NOVO Compositions of GLP-1 peptides and preparation thereof
Mar, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 20, 2022
New Chemical Entity Exclusivity(NCE) Dec 05, 2022
M(M-252) Jan 16, 2023

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: 05 December, 2021

Market Authorisation Date: 20 September, 2019

Treatment: NA

Dosage: TABLET

More Information on Dosage

RYBELSUS family patents

Family Patents

127. Rytelo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9375485 GERON Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
Mar, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-482) Jun 06, 2031

Drugs and Companies using IMETELSTAT SODIUM ingredient

Market Authorisation Date: 06 June, 2024

Treatment: Treatment of patients with myelodysplastic syndromes (mds) with transfusion-dependent anemia

Dosage: POWDER

More Information on Dosage

RYTELO family patents

Family Patents

128. Ryzodeg 70/30 patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9884094 NOVO Method of treating diabetes mellitus
May, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 16, 2019
New Chemical Entity Exclusivity(NCE) Sep 25, 2020

Drugs and Companies using INSULIN ASPART; INSULIN DEGLUDEC ingredient

NCE-1 date: 26 September, 2019

Market Authorisation Date: 25 September, 2015

Treatment: Method of improving glycemic control in patients with diabetes mellitus by administering a mixture of insulin degludec and insulin aspart during or around the time of the largest meal of the day

Dosage: SOLUTION

More Information on Dosage

RYZODEG 70/30 family patents

Family Patents

129. Scemblix patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8829195 NOVARTIS Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
May, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 29, 2026
New Indication(I-953) Oct 29, 2027
New Indication(I-954) Oct 29, 2027
ODE*(ODE*) Oct 29, 2028
Orphan Drug Exclusivity(ODE-381) Oct 29, 2028
Orphan Drug Exclusivity(ODE-382) Oct 29, 2028
Orphan Drug Exclusivity(ODE-499) Oct 29, 2031
Orphan Drug Exclusivity(ODE-500) Oct 29, 2031

Drugs and Companies using ASCIMINIB HYDROCHLORIDE ingredient

NCE-1 date: 29 October, 2025

Market Authorisation Date: 29 October, 2021

Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml)

Dosage: TABLET

More Information on Dosage

SCEMBLIX family patents

Family Patents

130. Secuado patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10814002 HISAMITSU Patch and method for producing the same
Jul, 2033

(8 years from now)

US9687474 HISAMITSU Patch
Jul, 2033

(8 years from now)

US10583121 HISAMITSU Patch
Jul, 2033

(8 years from now)

US11123305 HISAMITSU Patch
Jul, 2033

(8 years from now)

US10022445 HISAMITSU Patch
Jul, 2033

(8 years from now)

US11813364 HISAMITSU Patch
Sep, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 11, 2022

Drugs and Companies using ASENAPINE ingredient

Market Authorisation Date: 11 October, 2019

Treatment: Method of treating adults with schizophrenia comprising administering asenapine via a transdermal patch

Dosage: SYSTEM

More Information on Dosage

SECUADO family patents

Family Patents

131. Sesquient patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9493582 LUPIN Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(8 years from now)




Drugs and Companies using FOSPHENYTOIN SODIUM ingredient

Market Authorisation Date: 05 November, 2020

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

SESQUIENT family patents

Family Patents

132. Seysara patent expiration

Can you believe SEYSARA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9255068 ALMIRALL Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same
Feb, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 01, 2023

Drugs and Companies using SARECYCLINE HYDROCHLORIDE ingredient

NCE-1 date: 01 October, 2022

Market Authorisation Date: 01 October, 2018

Treatment: A method for treating acne in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering an effective amount of sarecycline hydroch...

Dosage: TABLET

More Information on Dosage

SEYSARA family patents

Family Patents

133. Skyclarys patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9701709 REATA PHARMS 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
Apr, 2033

(8 years from now)

US8993640 REATA PHARMS 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
Apr, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 28, 2028
Orphan Drug Exclusivity(ODE-427) Feb 28, 2030

Drugs and Companies using OMAVELOXOLONE ingredient

NCE-1 date: 28 February, 2027

Market Authorisation Date: 28 February, 2023

Treatment: NA

Dosage: CAPSULE

More Information on Dosage

SKYCLARYS family patents

Family Patents

134. Soaanz patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10154963 SARFE PHARMS Controlled-release formulations comprising Torsemide
Oct, 2033

(8 years from now)




Drugs and Companies using TORSEMIDE ingredient

Market Authorisation Date: 14 June, 2021

Treatment: NA

Dosage: TABLET

More Information on Dosage

SOAANZ family patents

Family Patents

135. Soliqua 100/33 patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9717852 SANOFI-AVENTIS US Cartridge holder and pen-type injector
Apr, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Nov 21, 2019
New Chemical Entity Exclusivity(NCE) Jul 27, 2021

Drugs and Companies using INSULIN GLARGINE; LIXISENATIDE ingredient

NCE-1 date: 27 July, 2020

Market Authorisation Date: 21 November, 2016

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

SOLIQUA 100/33 family patents

Family Patents

136. Sotyktu patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE47929 BRISTOL Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
Nov, 2033

(8 years from now)

US10000480 BRISTOL Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
Nov, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11021475 BRISTOL Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
Nov, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 09, 2027

Drugs and Companies using DEUCRAVACITINIB ingredient

NCE-1 date: 09 September, 2026

Market Authorisation Date: 09 September, 2022

Treatment: Treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Dosage: TABLET

More Information on Dosage

SOTYKTU family patents

Family Patents

137. Spravato patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785500 JANSSEN PHARMS Intranasal administration of ketamine to treat depression
Mar, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-840) Jul 31, 2023
NCE*(NCE*) Mar 05, 2024

Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 05 March, 2019

Treatment: Treatment of treatment-resistant depression in adult in conjunction with an oral antidepressant

Dosage: SPRAY

How can I launch a generic of SPRAVATO before it's drug patent expiration?
More Information on Dosage

SPRAVATO family patents

Family Patents

138. Stribild patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718

(Pediatric)

GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Apr, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 27, 2015
New Chemical Entity Exclusivity(NCE) Aug 27, 2017
New Indication(I-704) Dec 17, 2017
New Patient Population(NPP) Jan 27, 2020

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

NCE-1 date: 27 August, 2016

Market Authorisation Date: 27 August, 2012

Treatment: NA

Dosage: TABLET

How can I launch a generic of STRIBILD before it's drug patent expiration?
More Information on Dosage

STRIBILD family patents

Family Patents

139. Syfovre patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11661441 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
Jan, 2033

(8 years from now)

US10125171 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
Aug, 2033

(8 years from now)

US10875893 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(8 years from now)

US10035822 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(8 years from now)

US11292815 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 22, 2026
New Chemical Entity Exclusivity(NCE) May 14, 2026

Drugs and Companies using PEGCETACOPLAN ingredient

NCE-1 date: 14 May, 2025

Market Authorisation Date: 17 February, 2023

Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by intravitreal administration of pegcetacoplan

Dosage: SOLUTION

More Information on Dosage

SYFOVRE family patents

Family Patents

140. Symdeko (copackaged) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10058546 VERTEX PHARMS INC Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof
Jul, 2033

(8 years from now)

US9012496 VERTEX PHARMS INC Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
Jul, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jun 21, 2022
New Chemical Entity Exclusivity(NCE) Feb 12, 2023
Orphan Drug Exclusivity(ODE-173) Feb 12, 2025
Orphan Drug Exclusivity(ODE-247) Jun 21, 2026
Orphan Drug Exclusivity(ODE-335) Dec 21, 2027

Drugs and Companies using IVACAFTOR; IVACAFTOR, TEZACAFTOR ingredient

NCE-1 date: 12 February, 2022

Market Authorisation Date: 21 June, 2019

Treatment: Treatment of cf in patients 6 years and older who have a f508del or g551d cftr mutation and a 2nd mutation selected from r117h, a455e, 2789+5g->a, and 3849+10kbc->t, comprising concurrent coadministra...

Dosage: TABLET

More Information on Dosage

SYMDEKO (COPACKAGED) family patents

Family Patents

141. Symproic patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10952968 BDSI Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
May, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 23, 2022

Drugs and Companies using NALDEMEDINE TOSYLATE ingredient

NCE-1 date: 23 March, 2021

Market Authorisation Date: 23 March, 2017

Treatment: NA

Dosage: TABLET

More Information on Dosage

SYMPROIC family patents

Family Patents

142. Tafinlar patent expiration

TAFINLAR's oppositions filed in EPO
Can you believe TAFINLAR received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10869869 NOVARTIS Method of adjuvant cancer treatment
Aug, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-678) Jan 08, 2017
New Chemical Entity Exclusivity(NCE) May 29, 2018
M(M-170) Nov 20, 2018
Orphan Drug Exclusivity(ODE) May 29, 2020
Orphan Drug Exclusivity(ODE-47) May 29, 2020
New Indication(I-745) Jun 22, 2020
Orphan Drug Exclusivity(ODE-58) Jan 09, 2021
New Indication(I-778) Apr 30, 2021
New Indication(I-781) May 04, 2021
M(M-246) Oct 06, 2022
Orphan Drug Exclusivity(ODE-147) Jun 22, 2024
Orphan Drug Exclusivity(ODE-182) Apr 30, 2025
Orphan Drug Exclusivity(ODE-183) May 04, 2025
New Indication(I-894) Jun 22, 2025
Pediatric Exclusivity(PED) Sep 16, 2026
New Indication(I-908) Mar 16, 2026
New Product(NP) Mar 16, 2026
Orphan Drug Exclusivity(ODE-428) Mar 16, 2030

Drugs and Companies using DABRAFENIB MESYLATE ingredient

NCE-1 date: 22 December, 2024

Market Authorisation Date: 29 May, 2013

Treatment: Tafinlar(r) is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement o...

Dosage: CAPSULE

More Information on Dosage

TAFINLAR family patents

Family Patents

143. Tazverik patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10821113 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor
Apr, 2033

(8 years from now)

US9394283 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor
Apr, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9872862 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor
Apr, 2033

(8 years from now)

US11491163 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor
Apr, 2033

(8 years from now)

US10245269 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor
Apr, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-835) Jun 18, 2023
New Indication(I-836) Jun 18, 2023
New Chemical Entity Exclusivity(NCE) Jan 23, 2025
Orphan Drug Exclusivity(ODE-299) Jan 23, 2027
Orphan Drug Exclusivity(ODE-314) Jun 18, 2027

Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient

NCE-1 date: 24 January, 2024

Market Authorisation Date: 23 January, 2020

Treatment: Method of treating a lung metastasis of epithelioid sarcoma; Method of treating epithelioid sarcoma; Method of treating relapsed or refractory follicular lymphoma by inhibiting ezh2; Method of treatin...

Dosage: TABLET

More Information on Dosage

TAZVERIK family patents

Family Patents

144. Tibsovo patent expiration

Can you believe TIBSOVO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9850277 SERVIER Therapeutically active compositions and their methods of use
Jan, 2033

(8 years from now)

US9474779 SERVIER Therapeutically active compositions and their methods of use
Aug, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11667673 SERVIER Therapeutically active compounds and their methods of use
Jan, 2033

(8 years from now)

US10717764 SERVIER Therapeutically active compounds and their methods of use
Jan, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-816) May 02, 2022
New Chemical Entity Exclusivity(NCE) Jul 20, 2023
New Indication(I-875) Aug 25, 2024
New Indication(I-893) May 25, 2025
Orphan Drug Exclusivity(ODE-203) Jul 20, 2025
Orphan Drug Exclusivity(ODE-242) May 02, 2026
New Indication(I-924) Oct 24, 2026
Orphan Drug Exclusivity(ODE-368) Aug 25, 2028
Orphan Drug Exclusivity(ODE-447) Oct 24, 2030

Drugs and Companies using IVOSIDENIB ingredient

NCE-1 date: 20 July, 2022

Market Authorisation Date: 20 July, 2018

Treatment: A method of treating a cancer characterized by an idh1 mutation wherein the cancer is relapsed or refractory myelodysplastic syndromes; A method of treating previously treated, locally advanced or met...

Dosage: TABLET

How can I launch a generic of TIBSOVO before it's drug patent expiration?
More Information on Dosage

TIBSOVO family patents

Family Patents

145. Tigecycline patent expiration

Can you believe TIGECYCLINE received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9855335 AMNEAL Tigecycline composition for injection
Apr, 2033

(8 years from now)

US9855355 AMNEAL Method and device for plasma-treating hollow bodies
Apr, 2033

(8 years from now)




Drugs and Companies using TIGECYCLINE ingredient

Market Authorisation Date: 02 August, 2018

Treatment: NA

Dosage: POWDER

More Information on Dosage

TIGECYCLINE family patents

Family Patents

146. Tolsura patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9272046 MAYNE PHARMA Itraconazole compositions and dosage forms, and methods of using the same
Jun, 2033

(8 years from now)

US10463740 MAYNE PHARMA Itraconazole compositions and dosage forms, and methods of using the same
Jun, 2033

(8 years from now)

US9713642 MAYNE PHARMA Itraconazole compositions and dosage forms, and methods of using the same
Jun, 2033

(8 years from now)

US10806792 MAYNE PHARMA Itraconazole compositions and dosage forms, and methods of using the same
Jun, 2033

(8 years from now)

US8921374 MAYNE PHARMA Itraconazole compositions and dosage forms, and methods of using the same
Jun, 2033

(8 years from now)




Drugs and Companies using ITRACONAZOLE ingredient

Market Authorisation Date: 11 December, 2018

Treatment: Treatment of fungal infections, including blastomycosis, histoplasmosis, and aspergillosis

Dosage: CAPSULE

More Information on Dosage

TOLSURA family patents

Family Patents

147. Trikafta (copackaged) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11752106 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Feb, 2033

(8 years from now)

US10272046 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Feb, 2033

(8 years from now)

US8883206 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Feb, 2033

(8 years from now)

US11147770 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Feb, 2033

(8 years from now)

US9012496 VERTEX PHARMS INC Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
Jul, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jun 08, 2024
New Chemical Entity Exclusivity(NCE) Oct 21, 2024
New Product(NP) Apr 26, 2026
Orphan Drug Exclusivity(ODE-275) Oct 21, 2026
Orphan Drug Exclusivity(ODE-323) Dec 21, 2027
Orphan Drug Exclusivity(ODE-357) Jun 08, 2028
Orphan Drug Exclusivity(ODE-433) Apr 26, 2030

Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient

NCE-1 date: 22 October, 2023

Market Authorisation Date: 26 April, 2023

Treatment: Treatment of cf in patients aged 2 to <6 years who have at least one f508del mutation or a mutation in the cftr gene that is responsive based on in vitro data comprising administering a composition ac...

Dosage: GRANULES; TABLET

More Information on Dosage

TRIKAFTA (COPACKAGED) family patents

Family Patents

148. Trudhesa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10940278 IMPEL PHARMS Nozzles for nasal drug delivery
Jan, 2033

(8 years from now)

US9919117 IMPEL PHARMS Nozzles for nasal drug delivery
Mar, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 02, 2024

Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient

Market Authorisation Date: 02 September, 2021

Treatment: Nasal administration of dihydroergotamine mesylate by metered spray for the acute treatment of migraine with or without aura

Dosage: SPRAY, METERED

More Information on Dosage

TRUDHESA family patents

Family Patents

149. Truqap patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9487525 ASTRAZENECA Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide
Apr, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039766 ASTRAZENECA Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide
Apr, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 16, 2028

Drugs and Companies using CAPIVASERTIB ingredient

NCE-1 date: 17 November, 2027

Market Authorisation Date: 16 November, 2023

Treatment: Treatment with fulvestrant of hr-pos. her2-neg. locally advanced or metastatic breast cancer with pik3ca/akt1/pten-alteration(s) following progression on endocrine therapy in the metastatic setting or...

Dosage: TABLET

More Information on Dosage

TRUQAP family patents

Family Patents

150. Tukysa patent expiration

TUKYSA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11504370 SEAGEN Treatment of brain cancer
Mar, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 17, 2025
New Indication(I-906) Jan 19, 2026
Orphan Drug Exclusivity(ODE-309) Apr 17, 2027
Orphan Drug Exclusivity(ODE-422) Jan 19, 2030

Drugs and Companies using TUCATINIB ingredient

NCE-1 date: 17 April, 2024

Market Authorisation Date: 17 April, 2020

Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer

Dosage: TABLET

More Information on Dosage

TUKYSA family patents

Family Patents

151. Turalio patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7893075 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
May, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9358235 DAIICHI SANKYO INC Kinase modulation, and indications therefor
Jun, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 02, 2024
ODE*(ODE*) Aug 02, 2026
Orphan Drug Exclusivity(ODE-250) Aug 02, 2026

Drugs and Companies using PEXIDARTINIB HYDROCHLORIDE ingredient

NCE-1 date: 03 August, 2023

Market Authorisation Date: 14 October, 2022

Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery

Dosage: CAPSULE

More Information on Dosage

TURALIO family patents

Family Patents

152. Tybost patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718

(Pediatric)

GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Apr, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 27, 2017
New Product(NP) Sep 24, 2017
New Patient Population(NPP) Aug 22, 2022
Orphan Drug Exclusivity(ODE-260) Aug 22, 2026

Drugs and Companies using COBICISTAT ingredient

NCE-1 date: 27 August, 2016

Market Authorisation Date: 24 September, 2014

Treatment: NA

Dosage: TABLET

How can I launch a generic of TYBOST before it's drug patent expiration?
More Information on Dosage

TYBOST family patents

Family Patents

153. Ubrelvy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8912210 ABBVIE Piperidinone carboxamide azaindane CGRP receptor antagonists
Dec, 2033

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 23, 2024

Drugs and Companies using UBROGEPANT ingredient

NCE-1 date: 24 December, 2023

Market Authorisation Date: 23 December, 2019

Treatment: NA

Dosage: TABLET

More Information on Dosage

UBRELVY family patents

Family Patents

154. Ukoniq patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10570142 TG THERAPS Selective PI3K delta inhibitors
Jul, 2033

(8 years from now)

US9150579 TG THERAPS Selective PI3K delta inhibitors
Jul, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10072013 TG THERAPS Selective PI3K delta inhibitors
Jul, 2033

(8 years from now)

US9669033 TG THERAPS Selective PI3K delta inhibitors
Jul, 2033

(8 years from now)

US10981919 TG THERAPS Selective PI3K delta inhibitors
Jul, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 05, 2026
Orphan Drug Exclusivity(ODE-343) Feb 05, 2028
Orphan Drug Exclusivity(ODE-344) Feb 05, 2028

Drugs and Companies using UMBRALISIB TOSYLATE ingredient

NCE-1 date: 05 February, 2025

Market Authorisation Date: 05 February, 2021

Treatment: Relapsed or refractory follicular lymphoma (fl) who have received at least three prior lines of systemic therapy; Relapsed or refractory marginal zone lymphoma (mzl) who have received at least one pri...

Dosage: TABLET

More Information on Dosage

UKONIQ family patents

Family Patents

155. Ultravate patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8962028 MICAL PHARMS Topical steroid composition and method
Jun, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 06, 2018
New Patient Population(NPP) Aug 31, 2023

Drugs and Companies using HALOBETASOL PROPIONATE ingredient

Market Authorisation Date: 06 November, 2015

Treatment: Use of a lotion containing halobetasol propionate for the treatment of corticosteroid-responsive dermatoses including psoriasis

Dosage: LOTION

How can I launch a generic of ULTRAVATE before it's drug patent expiration?
More Information on Dosage

ULTRAVATE family patents

Family Patents

156. Uzedy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9023897 TEVA Biodegradable drug delivery compositions
Apr, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 28, 2026

Drugs and Companies using RISPERIDONE ingredient

Market Authorisation Date: 28 April, 2023

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

UZEDY family patents

Family Patents

157. Vanflyta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9675549 DAIICHI SANKYO INC Tablet containing composite with cyclodextrin
Sep, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 20, 2028
Orphan Drug Exclusivity(ODE-437) Jul 20, 2030

Drugs and Companies using QUIZARTINIB DIHYDROCHLORIDE ingredient

NCE-1 date: 21 July, 2027

Market Authorisation Date: 20 July, 2023

Treatment: NA

Dosage: TABLET

More Information on Dosage

VANFLYTA family patents

Family Patents

158. Vascepa patent expiration

VASCEPA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10786478 AMARIN PHARMS Methods of reducing the risk of cardiovascular events in a subject
Jun, 2033

(8 years from now)

US10555925 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Jun, 2033

(8 years from now)

US10668042 AMARIN PHARMS Methods of reducing the risk of cardiovascular events in a subject
Jun, 2033

(8 years from now)

US10278935 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Jun, 2033

(8 years from now)

US10278937 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Jun, 2033

(8 years from now)

US11298333 AMARIN PHARMS Methods of reducing the risk of cardiovascular events in a subject
Jun, 2033

(8 years from now)

US9603826 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Jun, 2033

(8 years from now)

US11116742 AMARIN PHARMS Methods of reducing the risk of cardiovascular events in a subject
Jun, 2033

(8 years from now)

US11000499 AMARIN PHARMS Methods of reducing the risk of cardiovascular events in a subject
Jun, 2033

(8 years from now)

US9693986 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Jun, 2033

(8 years from now)

US9693985 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Jun, 2033

(8 years from now)

US10792270 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Jun, 2033

(8 years from now)

US9918954 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Jun, 2033

(8 years from now)

US10894028 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Jun, 2033

(8 years from now)

US10576054 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Jun, 2033

(8 years from now)

US10383840 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Jun, 2033

(8 years from now)

US10555924 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Jun, 2033

(8 years from now)

US9623001 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Jun, 2033

(8 years from now)

US9693984 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Jun, 2033

(8 years from now)

US10278936 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Jun, 2033

(8 years from now)

US9610272 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Jun, 2033

(8 years from now)

US11369582 AMARIN PHARMS Methods of reducing the risk of cardiovascular events in a subject
Jun, 2033

(8 years from now)

US10568861 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Jun, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jul 26, 2015
New Chemical Entity Exclusivity(NCE) Jul 26, 2017
New Indication(I-819) Dec 13, 2022

Drugs and Companies using ICOSAPENT ETHYL ingredient

NCE-1 date: 26 July, 2016

Market Authorisation Date: 26 July, 2012

Treatment: Use of vascepa as an adjunct to statin therapy to reduce the risk of a second or further cardiovascular (cv) event in an adult patient with elevated tg levels (>= 150 mg/dl) and diabetes mellitus and ...

Dosage: CAPSULE

How can I launch a generic of VASCEPA before it's drug patent expiration?
More Information on Dosage

VASCEPA family patents

Family Patents

159. Veltassa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9492476 VIFOR PHARMA Potassium-binding agents for treating hypertension and hyperkalemia
Oct, 2033

(8 years from now)

US11123363 VIFOR PHARMA Potassium-binding agents for treating hypertension and hyperkalemia
Oct, 2033

(8 years from now)

US9925212 VIFOR PHARMA Potassium-binding agents for treating hypertension and hyperkalemia
Oct, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 21, 2020
New Patient Population(NPP) Oct 02, 2026
New Strength(NS) Oct 02, 2026

Drugs and Companies using PATIROMER SORBITEX CALCIUM ingredient

NCE-1 date: 22 October, 2019

Market Authorisation Date: 02 October, 2023

Treatment: Treatment of hyperkalemia

Dosage: POWDER

How can I launch a generic of VELTASSA before it's drug patent expiration?
More Information on Dosage

VELTASSA family patents

Family Patents

160. Vemlidy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9296769

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(8 years from now)

US8754065

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 11, 2019
New Chemical Entity Exclusivity(NCE) Nov 05, 2020
M(M-255) Feb 04, 2023
M(M-266) Aug 22, 2023
New Patient Population(NPP) Oct 17, 2025

Drugs and Companies using TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 10 November, 2016

Treatment: NA

Dosage: TABLET

How can I launch a generic of VEMLIDY before it's drug patent expiration?
More Information on Dosage

VEMLIDY family patents

Family Patents

161. Venclexta patent expiration

VENCLEXTA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10993942 ABBVIE Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
Sep, 2033

(8 years from now)

US11413282 ABBVIE Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
Sep, 2033

(8 years from now)

US11590128 ABBVIE Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
Sep, 2033

(8 years from now)

US9539251 ABBVIE Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
Sep, 2033

(8 years from now)

US11110087 ABBVIE Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
Sep, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 11, 2021
New Indication(I-782) Jun 08, 2021
M(M-228) Jun 08, 2021
New Indication(I-789) Nov 21, 2021
New Indication(I-795) May 15, 2022
Orphan Drug Exclusivity(ODE) Apr 11, 2023
Orphan Drug Exclusivity(ODE-114) Apr 11, 2023
M(M-265) Oct 16, 2023
Orphan Drug Exclusivity(ODE-185) Jun 08, 2025
Orphan Drug Exclusivity(ODE-211) Nov 21, 2025
Orphan Drug Exclusivity(ODE-239) May 15, 2026

Drugs and Companies using VENETOCLAX ingredient

NCE-1 date: 11 April, 2020

Market Authorisation Date: 11 April, 2016

Treatment: Treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up that includes a dose of 50 mg per day for...

Dosage: TABLET

How can I launch a generic of VENCLEXTA before it's drug patent expiration?
More Information on Dosage

VENCLEXTA family patents

Family Patents

162. Viberzi patent expiration

VIBERZI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11484527 ABBVIE Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

US11311516 ABBVIE Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

US9675587 ABBVIE Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

US11229627 ABBVIE Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

US11160792 ABBVIE Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

US12097187 ABBVIE Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

US11090291 ABBVIE Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

US11007179 ABBVIE Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

US10188632 ABBVIE Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 27, 2020

Drugs and Companies using ELUXADOLINE ingredient

NCE-1 date: 28 May, 2019

Market Authorisation Date: 27 May, 2015

Treatment: Reduction of the frequency of abdominal pain and diarrhea, in an inflammatory bowel disease with diarrhea (ibs-d) patient, with eluxadoline twice daily with food

Dosage: TABLET

How can I launch a generic of VIBERZI before it's drug patent expiration?
More Information on Dosage

VIBERZI family patents

Family Patents

163. Victoza patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265893

(Pediatric)

NOVO NORDISK INC Injection button
Mar, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 25, 2015
M(M-115) Apr 06, 2015
M(M-176) Apr 22, 2019
New Indication(I-750) Aug 25, 2020
New Patient Population(NPP) Jun 17, 2022
Pediatric Exclusivity(PED) Dec 17, 2022

Drugs and Companies using LIRAGLUTIDE ingredient

NCE-1 date: 17 December, 2021

Market Authorisation Date: 25 January, 2010

Treatment: NA

Dosage: SOLUTION

How can I launch a generic of VICTOZA before it's drug patent expiration?
More Information on Dosage

VICTOZA family patents

Family Patents

164. Viekira Pak (copackaged) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9629841 ABBVIE Formulations of pyrimidinedione derivative compounds
Oct, 2033

(8 years from now)

US10201542 ABBVIE Formulations of pyrimidinedione derivative compounds
Oct, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-163) Apr 22, 2019
New Chemical Entity Exclusivity(NCE) Dec 19, 2019

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient

NCE-1 date: 19 December, 2018

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of hcv infection using dasabuvir

Dosage: TABLET

More Information on Dosage

VIEKIRA PAK (COPACKAGED) family patents

Family Patents

165. Vijoice patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8227462 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Apr, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 24, 2024
Orphan Drug Exclusivity(ODE-396) Apr 05, 2029

Drugs and Companies using ALPELISIB ingredient

NCE-1 date: 25 May, 2023

Market Authorisation Date: 05 April, 2022

Treatment: NA

Dosage: TABLET; GRANULES

More Information on Dosage

VIJOICE family patents

Family Patents

166. Vivjoa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11247981 MYCOVIA PHARMS Metalloenzyme inhibitor compounds
May, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 26, 2027
Generating Antibiotic Incentives Now(GAIN) Apr 26, 2032

Drugs and Companies using OTESECONAZOLE ingredient

NCE-1 date: 27 April, 2031

Market Authorisation Date: 26 April, 2022

Treatment: Vivjoa is indicated to reduce the incidence of recurrent vulvovaginal candidiasis (rvvc) in females with a history of rvvc who are not of reproductive potential

Dosage: CAPSULE

More Information on Dosage

VIVJOA family patents

Family Patents

167. Vivlodex patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9526734 ICEUTICA OPERATIONS Formulation of meloxicam
Mar, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 22, 2018

Drugs and Companies using MELOXICAM ingredient

Market Authorisation Date: 22 October, 2015

Treatment: NA

Dosage: CAPSULE

How can I launch a generic of VIVLODEX before it's drug patent expiration?
More Information on Dosage

VIVLODEX family patents

Family Patents

168. Vosevi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8575135

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(8 years from now)

US8921341

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(8 years from now)

US8940718

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 18, 2022

Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient

NCE-1 date: 18 July, 2021

Market Authorisation Date: 18 July, 2017

Treatment: NA

Dosage: TABLET

More Information on Dosage

VOSEVI family patents

Family Patents

169. Vumerity patent expiration

VUMERITY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8669281 BIOGEN INC Prodrugs of fumarates and their use in treating various diseases
Sep, 2033

(8 years from now)

US10080733 BIOGEN INC Prodrugs of fumarates and their use in treating various diseases
Sep, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9090558 BIOGEN INC Prodrugs of fumarates and their use in treating various diseases
Sep, 2033

(8 years from now)




Drugs and Companies using DIROXIMEL FUMARATE ingredient

Market Authorisation Date: 29 October, 2019

Treatment: Method of treating multiple sclerosis

Dosage: CAPSULE, DELAYED RELEASE

How can I launch a generic of VUMERITY before it's drug patent expiration?
More Information on Dosage

VUMERITY family patents

Family Patents

170. Vyleesi (autoinjector) patent expiration

VYLEESI (AUTOINJECTOR)'s oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9352013 COSETTE Uses of bremelanotide in therapy for female sexual dysfunction
Nov, 2033

(8 years from now)

US10286034 COSETTE Uses of bremelanotide in therapy for female sexual dysfunction
Nov, 2033

(8 years from now)

US9700592 COSETTE Uses of bremelanotide in therapy for female sexual dysfunction
Nov, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 21, 2024

Drugs and Companies using BREMELANOTIDE ACETATE ingredient

NCE-1 date: 22 June, 2023

Market Authorisation Date: 21 June, 2019

Treatment: Treatment of hypoactive sexual desire disorder (hsdd)

Dosage: SOLUTION

More Information on Dosage

VYLEESI (AUTOINJECTOR) family patents

Family Patents

171. Wegovy patent expiration

WEGOVY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9764003 NOVO Use of long-acting GLP-1 peptides
Jun, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 05, 2022
New Product(NP) Jun 04, 2024
New Patient Population(NPP) Dec 23, 2025
New Dosing Schedule(D-190) Jul 21, 2026
New Indication(I-935) Mar 08, 2027

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: 05 December, 2021

Market Authorisation Date: 04 June, 2021

Treatment: Method for weight management according to a dose escalation schedule

Dosage: SOLUTION

How can I launch a generic of WEGOVY before it's drug patent expiration?
More Information on Dosage

WEGOVY family patents

Family Patents

172. Xacduro (copackaged) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9309245 ENTASIS THERAP Beta-lactamase inhibitor compounds
Apr, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9623014 ENTASIS THERAP β-lactamase inhibitor compounds
Apr, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 23, 2028
Generating Antibiotic Incentives Now(GAIN) May 23, 2033

Drugs and Companies using DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM ingredient

NCE-1 date: 23 May, 2032

Market Authorisation Date: 23 May, 2023

Treatment: Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp)

Dosage: POWDER

More Information on Dosage

XACDURO (COPACKAGED) family patents

Family Patents

173. Xaracoll patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11746141 INNOCOLL PHARMS Modified collagen
Jan, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 28, 2023

Drugs and Companies using BUPIVACAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 August, 2020

Treatment: NA

Dosage: IMPLANT

More Information on Dosage

XARACOLL family patents

Family Patents

174. Xatmep patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11969503 AZURITY Methotrexate composition
Jan, 2033

(8 years from now)

US11116724 AZURITY Methotrexate composition
Jan, 2033

(8 years from now)

US10231927 AZURITY Methotrexate composition
Jan, 2033

(8 years from now)

US9259427 AZURITY Methotrexate composition
Jan, 2033

(8 years from now)

US10610485 AZURITY Methotrexate composition
Jan, 2033

(8 years from now)

US9855215 AZURITY Methotrexate composition
Jan, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Apr 25, 2024
Orphan Drug Exclusivity(ODE-137) Apr 25, 2024
Orphan Drug Exclusivity(ODE-138) Apr 25, 2024

Drugs and Companies using METHOTREXATE SODIUM ingredient

Market Authorisation Date: 25 April, 2017

Treatment: A method for treating acute lymphoblastic leukemia; Treatment of juvenile rheumatoid arthritis

Dosage: SOLUTION

More Information on Dosage

XATMEP family patents

Family Patents

175. Xelstrym patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9456993 NOVEN PHARMS INC Compositions and methods for transdermal delivery of amphetamine
Oct, 2033

(8 years from now)

US9474722 NOVEN PHARMS INC Compositions and methods for transdermal delivery of amphetamine
Oct, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 22, 2025

Drugs and Companies using DEXTROAMPHETAMINE ingredient

Market Authorisation Date: 22 March, 2022

Treatment: A method of treating attention deficit hyperactivity disorder by administering a transdermal composition containing amphetamine

Dosage: SYSTEM

More Information on Dosage

XELSTRYM family patents

Family Patents

176. Xhance patent expiration

XHANCE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11033696 OPTINOSE US INC Nasal delivery devices
May, 2033

(8 years from now)

US10179216 OPTINOSE US INC Nasal delivery devices
Jul, 2033

(8 years from now)

US10478574 OPTINOSE US INC Nasal administration
Nov, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 18, 2020
New Indication(I-940) Mar 15, 2027

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 18 September, 2017

Treatment: Method of delivering fluticasone propionate to a nasal airway

Dosage: SPRAY, METERED

More Information on Dosage

XHANCE family patents

Family Patents

177. Xiidra patent expiration

Can you believe XIIDRA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9085553 BAUSCH AND LOMB INC LFA-1 inhibitor and methods of preparation and polymorph thereof
Jul, 2033

(8 years from now)

US11058677 BAUSCH AND LOMB INC LFA-1 inhibitor formulations
Dec, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 11, 2021

Drugs and Companies using LIFITEGRAST ingredient

NCE-1 date: 11 July, 2020

Market Authorisation Date: 11 July, 2016

Treatment: NA

Dosage: SOLUTION/DROPS

How can I launch a generic of XIIDRA before it's drug patent expiration?
More Information on Dosage

XIIDRA family patents

Family Patents

178. Xipere patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636332 BAUSCH AND LOMB INC Methods and devices for the treatment of ocular diseases in human subjects
Nov, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 22, 2024

Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient

Market Authorisation Date: 22 October, 2021

Treatment: Treatment of macular edema associated with uveitis

Dosage: SUSPENSION

More Information on Dosage

XIPERE family patents

Family Patents

179. Xphozah patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8541448 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Aug, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 12, 2024
New Product(NP) Oct 17, 2026

Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient

NCE-1 date: 13 September, 2023

Market Authorisation Date: 17 October, 2023

Treatment: NA

Dosage: TABLET

More Information on Dosage

XPHOZAH family patents

Family Patents

180. Xpovio patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8999996 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof
Jul, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-837) Jun 22, 2023
New Chemical Entity Exclusivity(NCE) Jul 03, 2024
ODE*(ODE*) Jun 22, 2027
Orphan Drug Exclusivity(ODE-257) Jul 03, 2026
Orphan Drug Exclusivity(ODE-310) Jun 22, 2027
Orphan Drug Exclusivity(ODE-346) Dec 18, 2027

Drugs and Companies using SELINEXOR ingredient

NCE-1 date: 04 July, 2023

Market Authorisation Date: 03 July, 2019

Treatment: NA

Dosage: TABLET

More Information on Dosage

XPOVIO family patents

Family Patents

181. Xtandi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11839689 ASTELLAS Formulations of enzalutamide
Sep, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 31, 2017
New Indication(I-693) Sep 10, 2017
New Indication(I-786) Jul 13, 2021
New Indication(I-808) Dec 16, 2022
New Indication(I-926) Nov 17, 2026

Drugs and Companies using ENZALUTAMIDE ingredient

Market Authorisation Date: 04 August, 2020

Treatment: NA

Dosage: TABLET

How can I launch a generic of XTANDI before it's drug patent expiration?
More Information on Dosage

XTANDI family patents

Family Patents

182. Xtoro patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9504691 FONSECA BIOSCIENCES Finafloxacin suspension compositions
Nov, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 17, 2019
Pediatric Exclusivity(PED) Jun 17, 2020

Drugs and Companies using FINAFLOXACIN ingredient

NCE-1 date: 18 June, 2019

Market Authorisation Date: 17 December, 2014

Treatment: Treatment of acute otitis externa

Dosage: SUSPENSION/DROPS

More Information on Dosage

XTORO family patents

Family Patents

183. Xyosted (autoinjector) patent expiration

Can you believe XYOSTED (AUTOINJECTOR) received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11844804 ANTARES PHARMA INC Administration of testosterone compositions
Jun, 2033

(8 years from now)

US10821072 ANTARES PHARMA INC Needle assisted jet injection administration of testosterone compositions
Jun, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 28, 2021

Drugs and Companies using TESTOSTERONE ENANTHATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Method of administering testosterone enanthate subcutaneously

Dosage: SOLUTION

More Information on Dosage

XYOSTED (AUTOINJECTOR) family patents

Family Patents

184. Xyrem patent expiration

XYREM's oppositions filed in EPO
XYREM IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9486426 JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(8 years from now)

US10864181 JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(8 years from now)

US10213400 JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(8 years from now)

US11986446 JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(8 years from now)

US11253494 JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(8 years from now)

US8772306 JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(8 years from now)

US9050302 JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(8 years from now)

US8772306

(Pediatric)

JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(8 years from now)

US10864181

(Pediatric)

JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(8 years from now)

US9486426

(Pediatric)

JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(8 years from now)

US9050302

(Pediatric)

JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(8 years from now)

US11253494

(Pediatric)

JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(8 years from now)

US10213400

(Pediatric)

JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Nov 18, 2012
New Patient Population(NPP) Oct 26, 2021
Orphan Drug Exclusivity(ODE-231) Oct 26, 2025
Pediatric Exclusivity(PED) Apr 26, 2026

Drugs and Companies using SODIUM OXYBATE ingredient

Market Authorisation Date: 17 July, 2002

Treatment: Method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy patients with sodium oxybate when divalproex sodium is concomitantly administered.; Method of reducing adverse effects in...

Dosage: SOLUTION

How can I launch a generic of XYREM before it's drug patent expiration?
More Information on Dosage

XYREM family patents

Family Patents

185. Xywav patent expiration

XYWAV's oppositions filed in EPO
XYWAV IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8591922 JAZZ Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
Jan, 2033

(8 years from now)

US9132107 JAZZ Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
Jan, 2033

(8 years from now)

US11554102 JAZZ Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders
Jan, 2033

(8 years from now)

US8901173 JAZZ Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
Jan, 2033

(8 years from now)

US10675258 JAZZ Method of using gamma-hydroxybutyrate compositions for the treatment of disorders
Jan, 2033

(8 years from now)

US10195168 JAZZ Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders
Jan, 2033

(8 years from now)

US10864181 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(8 years from now)

US11253494 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(8 years from now)

US11986446 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(8 years from now)

US9050302 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(8 years from now)

US10213400 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(8 years from now)

US9486426 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(8 years from now)

US8772306 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(8 years from now)

US9050302

(Pediatric)

JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(8 years from now)

US9486426

(Pediatric)

JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(8 years from now)

US11253494

(Pediatric)

JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(8 years from now)

US10213400

(Pediatric)

JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(8 years from now)

US10864181

(Pediatric)

JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(8 years from now)

US8772306

(Pediatric)

JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jul 21, 2023
New Indication(I-870) Aug 12, 2024
Orphan Drug Exclusivity(ODE-231) Jul 21, 2027
Orphan Drug Exclusivity(ODE-361) Jul 21, 2027
Pediatric Exclusivity(PED) Jan 21, 2028
Orphan Drug Exclusivity(ODE-369) Aug 12, 2028

Drugs and Companies using CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE ingredient

Market Authorisation Date: 21 July, 2020

Treatment: Treatment of cataplexy or excessive daytime sleepiness (eds) in patients 7 years of age and older with narcolepsy with a mixture of sodium, potassium, magnesium, and calcium salts of ghb; Method of tr...

Dosage: SOLUTION

How can I launch a generic of XYWAV before it's drug patent expiration?
More Information on Dosage

XYWAV family patents

Family Patents

186. Yosprala patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9987231 GENUS LIFESCIENCES Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
Jan, 2033

(8 years from now)

US9539214 GENUS LIFESCIENCES Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
Mar, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Sep 14, 2019

Drugs and Companies using ASPIRIN; OMEPRAZOLE ingredient

Market Authorisation Date: 14 September, 2016

Treatment: For secondary prevention of cardiovascular and cerebrovascular events in patients at risk of developing aspirin-associated gastric ulcers; Treatment or secondary prevention of cardiovascular disease, ...

Dosage: TABLET, DELAYED RELEASE

How can I launch a generic of YOSPRALA before it's drug patent expiration?
More Information on Dosage

YOSPRALA family patents

Family Patents

187. Zerviate patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9254286

(Pediatric)

HARROW EYE Ophthalmic formulations of cetirizine and methods of use
Jan, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) May 30, 2020
Pediatric Exclusivity(PED) Nov 30, 2020

Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 May, 2017

Treatment: NA

Dosage: SOLUTION/DROPS

More Information on Dosage

ZERVIATE family patents

Family Patents

188. Zohydro Er patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9421200 RECRO GAINESVILLE Treating pain in patients with hepatic impairment
Jul, 2033

(8 years from now)

US9339499 RECRO GAINESVILLE Treating pain in patients with hepatic impairment
Jul, 2033

(8 years from now)

US9326982 RECRO GAINESVILLE Treating pain in patients with hepatic impairment
Jul, 2033

(8 years from now)

US9433619 RECRO GAINESVILLE Treating pain in patients with hepatic impairment
Jul, 2033

(8 years from now)

US9265760 RECRO GAINESVILLE Treating pain in patients with hepatic impairment
Jul, 2033

(8 years from now)

US9333201 RECRO GAINESVILLE Treating pain in patients with hepatic impairment
Jul, 2033

(8 years from now)

US10028946 RECRO GAINESVILLE Treating pain in patients with hepatic impairment
Jul, 2033

(8 years from now)

US9610286 RECRO GAINESVILLE Treating pain in patients with hepatic impairment
Jul, 2033

(8 years from now)

US10322120 RECRO GAINESVILLE Treating pain in patients with hepatic impairment
Jul, 2033

(8 years from now)

US10456393 RECRO GAINESVILLE Treating pain in patients with hepatic impairment
Jul, 2033

(8 years from now)

US10722511 RECRO GAINESVILLE Treating pain in patients with hepatic impairment
Jul, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 25, 2016

Drugs and Companies using HYDROCODONE BITARTRATE ingredient

Market Authorisation Date: 25 October, 2013

Treatment: Treatment of pain in patients with hepatic impairment

Dosage: CAPSULE, EXTENDED RELEASE

How can I launch a generic of ZOHYDRO ER before it's drug patent expiration?
More Information on Dosage

ZOHYDRO ER family patents

Family Patents

189. Zulresso patent expiration

ZULRESSO's oppositions filed in EPO
Can you believe ZULRESSO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10322139 SAGE THERAP Neuroactive steroid formulations and methods of treating CNS disorders
Jan, 2033

(8 years from now)

US10251894 SAGE THERAP Anticonvulsant activity of steroids
Nov, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 17, 2024
New Patient Population(NPP) Jun 16, 2025

Drugs and Companies using BREXANOLONE ingredient

NCE-1 date: 18 June, 2023

Market Authorisation Date: 17 June, 2019

Treatment: Method of treating postpartum depression

Dosage: SOLUTION

More Information on Dosage

ZULRESSO family patents

Family Patents

190. Zydelig patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10730879 GILEAD SCIENCES INC Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
Mar, 2033

(8 years from now)

US8865730 GILEAD SCIENCES INC Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
Mar, 2033

(8 years from now)

US9469643 GILEAD SCIENCES INC Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
Sep, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 23, 2019
Orphan Drug Exclusivity(ODE) Jul 23, 2021
Orphan Drug Exclusivity(ODE-70) Jul 23, 2021
Orphan Drug Exclusivity(ODE-71) Jul 23, 2021

Drugs and Companies using IDELALISIB ingredient

NCE-1 date: 23 July, 2018

Market Authorisation Date: 23 July, 2014

Treatment: For the treatment of patients with cll, fl, or sll

Dosage: TABLET

How can I launch a generic of ZYDELIG before it's drug patent expiration?
More Information on Dosage

ZYDELIG family patents

Family Patents

List of large molecules

1. List of Humira large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US9334319 ABBVIE INC. Low acidic species compositions
Mar, 2033

(8 years from now)

US9181572 ABBVIE INC. Methods to modulate lysine variant distribution
Mar, 2033

(8 years from now)

US9181337 ABBVIE INC. Modulated lysine variant species compositions and methods for producing and using the same
Mar, 2033

(8 years from now)

US9708400 ABBVIE INC. Methods to modulate lysine variant distribution
Mar, 2033

(8 years from now)

US9346879 ABBVIE INC. Protein purification methods to reduce acidic species
Mar, 2033

(8 years from now)

US9499616 ABBVIE INC. Modulated lysine variant species compositions and methods for producing and using the same
Mar, 2033

(8 years from now)

US9359434 ABBVIE INC. Cell culture methods to reduce acidic species
Mar, 2033

(8 years from now)

US9085618 ABBVIE INC. Low acidic species compositions and methods for producing and using the same
Mar, 2033

(8 years from now)

US9290568 ABBVIE INC. Methods to control protein heterogeneity
Mar, 2033

(8 years from now)

US9315574 ABBVIE INC. Low acidic species compositions and methods for producing and using the same
Apr, 2033

(8 years from now)

US9150645 ABBVIE INC. Cell culture methods to reduce acidic species
May, 2033

(8 years from now)

US9266949 ABBVIE INC. Low acidic species compositions and methods for producing and using the same
May, 2033

(8 years from now)

Ingredients: ADALIMUMAB

2. List of Stelara large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US9663810 JANSSEN BIOTECH, INC. Methods of cell culture
Mar, 2033

(8 years from now)

US9217168 JANSSEN BIOTECH, INC. Methods of cell culture
Mar, 2033

(8 years from now)

Ingredients: USTEKINUMAB

3. List of Actemra large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US10590164 GENENTECH, INC. Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
Mar, 2033

(8 years from now)

US9630988 GENENTECH, INC. Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
Jun, 2033

(8 years from now)

Ingredients: TOCILIZUMAB

4. List of Prolia And Xgeva large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US11486883 AMGEN INC. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
Mar, 2033

(8 years from now)

Ingredients: DENOSUMAB

5. List of Tysabri large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US9562252 BIOGEN INC. Methods of preventing and removing trisulfide bonds
May, 2033

(8 years from now)

Ingredients: NATALIZUMAB

6. List of Lucentis large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US10421984 GENENTECH, INC. Methods for reducing norleucine misincorporation into proteins using a microorganism comprising a mutant metA allele
Sep, 2033

(8 years from now)

Ingredients: RANIBIZUMAB

7. List of Avastin large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US10906934 GENENTECH, INC. Protein purification methods
Oct, 2033

(8 years from now)

Ingredients: BEVACIZUMAB